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ABSTRACT 
 
The aim of our this study was to investigate the role iron serum status, serum vascular 
endothelial growth factor and oxidative stress pattern in canine cancer patients with 
particular attention on cutaneous mast cell tumour.  Mast cell tumors (MCTs) are the most 
common cutaneous tumor in the dog, accounting for 16% to 21% of cutaneous tumors 
(Bostock,1986; Finnie,1979; Rothwell, 1987; Brodey,1970). Wide variation is seen in the histologic 
pattern of canine MCT, and the histologic grade has been clearly established as a strong 
prognostic factor that is highly predictive of biologic behavior and clinical outcome. It has 
been demonstrated that mast cells and mast cells tumour can express, produce and 
release the Vascular endothelial growth factor (VEGF) has been implicated to contribute 
tissue edema through its effect on vascular permeability (Paturno, 2009; Mederle, 2010).  
Studies performed in vitro and in vivo (rats) on Mast cells, showed also how VEGF 
expression was regulated by hypoxiainducible factor-1a (HIF-1a) activation through the 
phosphatidylinositol 3-kinase (PI3K)–HIF-1a pathway (Lee, 2008). Systemic hypoxia 
produces an inflammatory response characterized by increases in reactive O2 species 
(ROS), venular leukocyte-endothelial adherence and emigration, and vascular 
permeability. The results showed that mast cells could play a key role in hypoxia-induced 
inflammation and suggested that alterations in the ROS-nitric oxide balance may be 
involved in mast cell activation during hypoxia (Steiner, 2003). Studies performed in vitro 
on mast cells have also demonstrated the role of the antioxidant barrier, especially of the 
vitamin E, in prevent degranulation of mast cells and proliferation of tumour cell lines 
(Gueck, 2002; Reiter, 2003). Most of these study have been performed in vitro and, except 
for the VEGF (which has been often investigated in the last years for his role in the 
anticancer target therapy in veterinary medicine), there are just few data on the role of 
oxidative stress pattern and iron profile in canine patients affected by mast cell tumour, as 
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well as in several other neoplastic disease. These data are just assumed from human 
studies where both in vitro and in vivo a network between iron serum profile, VEGF and 
oxidative stress pattern has been established as they are involved in the progression of 
neoplastic diseases as well as in the body’s response to the tumour. So the aim of this 
study was to investigate the role of this network in canine oncology patients through 
different tumour time and clinical substage focusing on mast cell tumour. 
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INTRODUCTION 
 
Neo-angiogenesis plays a crucial role in tumour development, spreading and 
growths of metastatic disease. Although several different molecules and pathways 
are responsible of this complex event, the Vascular Endothelial Growth Factor 
(VEGF) is recognized as one of the main pro-angiogenetic factors (Folkman, 1992). 
In the early stage of tumour development, we observe a first a-vascular stage in 
which the tumour obtains oxygen and nutrients through the process of diffusion 
and simple diffusion (Grupta, 2003), and this stage the tumour is quiescent (Dvorak, 
1986). A tumour is composed by a heterogenic population of cells and some of the 
them, due to molecular changes, increased characteristic of malignancy, inhibition 
of onco-suppressor genes (such as RAS, Raf and p53) (Chiarugi V., 1998), or due to 
any inflammatory or traumatic event acquiring an angiogenetic phenotype. The 
acquisition and expression of this phenotype allows the formation of an adequate 
vascular bed and the consequent exponential growth of the tumour. The 
angiogenesis is supported and promoted by the VEGF secreted by the tumor cells 
and also by stromal cells, platelets, the immune system (mast cells, macrophages, 
T lymphocytes) and vascular cells, particularly in hypoxic areas. Hypoxia leads to 
the production of HIF, hypoxia-inducible factor, a transcription factor that 
stimulates the transcription of the VEGF encoding gene. Angiogenesis, as well as 
be an essential process for the growth of primary tumor, has a special importance 
in enabling metastatic spread. In fact the new vessels, because of their thin wall 
with poor development of the basement membrane, are easily traversed by the 
neoplastic cells, representing a convenient access route to the bloodstream 
(Papetti, 2002).  
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Iron is essential for life, is a cofactor of several oxide reductive enzymes, and is 
involved in oxygen transport and storage and in DNA synthesis. A small amount of 
the body iron is exchanged with the outside world and much of it is recycled; iron 
resulting by physiological cells’ death is collected by macrophages, re-entering the 
life cycle. Body iron levels are then set only during absorption through the small 
intestine and the small amount of iron that is lost must be replenished daily to 
maintain balance (Finch, 1982). If not, either because of an excessive loss or 
because the amount absorbed is not enough, we observe an iron deficiency that, 
over the time, will lead to the development of anemia. On the other hand, if the 
amount of iron entering the body exceeded the its requirements, this will be slowly 
accumulated in the body and particularly in the liver, leading to the development of 
iron overload. Due to the oxide-reducing capacity of the iron, this event will may 
lead to the formation of oxygen reactive species (ROS) that can damage cellular 
(Gomme, 2005).  
Vitamin E is a powerful antioxidant capable of blocking the lipid peroxidation of cell 
membranes, breaking the covalent bonds formed between ROS and fatty acids of 
the cell membrane. Iron deficiency increase HIF-1a and VEGF serum 
concentration and it is a promoter of angiogenesis, suggesting that systemic iron 
deficiency could play an important role in tumor progression (Eckard,  2010).  
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1. Vascular Endothelial Growth Factor (VEGF) 
 
 
1.1. VASCULOGENESIS AND ANGIOGENESIS 
 
The formation of new blood vessels can develop from two different process, 
vasculogenesis and angiogenesis. Although the vasculogenesis is the process of de-
novo formation of vessels from haemangioblast stem cells  which occurs in the early 
stages of embryogenesis (Risau, 1995; Patan, 2004), endothelial cell precursors are also 
found within the bone marrow of adults and are recruited due to trauma or ischemia 
(Zammaretti, 2005). During angiogenesis, the new vessels are sprouting from endothelial 
cells of preexisting vessels and despite angiogenesis is one of the main cause of solid 
tumor growth and progression it is also involved in inflammatory process (Asahara, 1997; 
Djonov, 2000; Peichev, 2000; Djonov, 2003; Patan, 2004) showing also important physiological 
function, such as wound healing (Ruiter,.1993; Paavonen, 2000). 
In adults the vascular system is almost quiescent, except during physiological process 
like wound healing, hair growth and the menstruation (Salven, 2001, Ferrara, 2001). In 
these circumstances the angiogenic mechanism is closely controlled and remains 
active for relatively short periods; 
The imbalance in demand and 
supply of oxygen and nutrients,  
as for example chronic 
inflammatory conditions 
(rheumatoid arthritis, 
inflammatory bowel disease), 
diabetes (diabetic retinopathy), 
inflammatory and 
Ramirez-Bergeron, 2006 
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hyperproliferative skin diseases such as psoriasis, endometriosis and tumours (Salven, 
2001) results in sprouting of new capillaries from pre-existing vessels  through 
angiogenesis.  
The study of the ability of a neoplastic tissue to induce formation of a new vascular 
network was one of the main objectives scientific researches over the past decade. 
Understanding this mechanism has allowed in human medicine to support the 
chemotherapy "standard" therapies, which aim to inhibition of tumor growth and 
treatment of both the primary tumor, both of possible metastatic spread. The tumor 
angiogenesis is a process formation of a vascular network within a tissue neoplastic 
and departing from it. Solid tumors are strictly dependent on the formation of new 
vessels, "a fabric cancer without a vascular bed can not grow larger than the diameter 
of 1-2 mm (Folkman, 1992). In pre-neoplastic vascular tissue seldom exceeds 2 mm in 
size (eg, carcinoma in situ) and, at this stage the cells can get oxygen and nutrients 
needed for survival and growth, and eliminate catabolites produced through a process 
of simple passive diffusion (Gupta, 2003). Besides this extension, this mechanism is not 
sufficient to trophic ensure the growth of tumors, also, the state of hypoxia that is 
established, leads via activation of p53, apoptosis (Cotran, 1999). At this stage, a tumour 
may remain quiescent for a long time, reaching a balance between the number 
replicating cells and those who are dying, until the time in which some of them switch 
to an angiogenic phenotype (List, 2001).  
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The angiogenic switch is a phenomenon caused by a rearrangement of gene 
expression, responsible of the balance between the factors stimulating and inhibiting 
angiogenesis. The acquisition of this phenotype by some tumour cells allows the 
formation of a proper vascular growth and the secondary tumour growth facilitating the 
metastatic process.  
The local vessel growth is induced by the release of angiogenic soluble factors by the 
involved tissue activating endothelial cells. The interactions between angiogenic 
factors and their receptors provide signals for cell migration, proliferation and 
differentiation forming new capillaries. As previously mentioned, angiogenesis is a 
complex process, characterized by a cascade of 
events such as an initial vasodilatation 
accompanied by an increase of vascular 
permeability and degradation of surrounding 
matrix, allowing activated endothelial cells in 
BioJobBlogger,2006
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proliferation and migration forming new vessels. The vessels derived from the 
sprouting of endothelial cells are supported by a network of differentiated endothelial 
cells and peri-matrix. Subsequently, at a stage of maturation and remodelling, these 
new vessels take place in the formation of a vascular network. The invasion of 
endothelial cells and their migration require the presence of various enzymatic 
activities such as plasminogen activator, metalloproteinase and various cysteine 
proteases (Mignatti, 1996). The expression of protease genes is induced by cytokines 
and angiogenic factors such as of the basic fibroblast growth factor (FGFb) and 
vascular endothelial growth factor (VEGF), while proteolysis is stimulated by the 
activation of pro-proteases on the one hand, and in decreasing levels of endogenous 
inhibitors proteolytic enzymes. The activated endothelial cells express integrin-like 
αvβ3 e αvβ5  that allow the migration through the degraded matrix, followed by their 
proliferation. Subsequently, the endothelial cells of new born capillaries synthesize a 
new basement membrane. In addition, the stabilization of new capillaries is 
accompanied by recruitment of pericytes and smooth muscle cells (Crocker, 1970). This 
process is regulated by the platelet derived growth factor (PDGF) (Lindahl, 1997; 
Hellström, 2001). The process of angiogenesis is tightly controlled by a dynamic balance 
between pro-angiogenic factors and anti-angiogenic factors (i.e. Thrombospondin-1). 
In physiological conditions the balance between pro angiogenic and anti angiogenic 
factors shifts in favour of the latter. 
There is ample evidence for recognizing VEGF as the main pro-angiogenic factor 
(Ferrara, 1999). The VEGF stimulates endothelial cells to degrade their basement 
membrane, migrate and express integrins αvβ3 e αvβ5 . Furthermore, VEGF is able to 
stimulate in vitro survival and proliferation of endothelial cells and the tube formation 
by endothelial cells themselves. 
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1.2. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 
 
VEGF is a dimeric glycoprotein of about 40 kDa and is a potent mitogen stimulating 
the proliferation and migration of endothelial cells, expression of metalloproteinases 
(Pufe, 2004) and the formation of endothelial fenestrations (Monaghan-Benson, 2009). VEGF 
also induces the increase of vascular permeability causing extravasal accumulation of 
fibrin (the substrate for the activity of endothelial cells and tumor cells) and finally, 
interacts with the cells of the immune system (including natural killer) inducing the 
expression of adhesion molecules. 
In mammals, the VEGF family comprises seven members: VEGF-A (usually the one 
considered as VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E and PlGF (placental 
growth factor). Alternative splicing results in different variants of VEGF that include 
VEGF121, VEGF165, and VEGF189 VEGF206, and several other forms. The solubility of 
these variants depends on the affinity for heparin. The VEGF206 and VEGF189 are 
soluble forms that do not bind tightly to heparin and, therefore, remain sequestered in 
the extracellular matrix. The VEGF165 binds heparin with lower affinity, but may also 
be associated with the matrix, while the VEGF121 lacks the ability to bind heparin and 
is therefore the more soluble form of VEGF. The VEGF-A is involved in the increased 
vascular permeability and angiogenesis. The VEGF-B is currently being studied for its 
role in tumor progression and seems not to be linked to angiogenesis, whereas 
VEGF-C and VEGF-D are widely studied for their role in angiogenesis and 
linfoangiogenesis in cancer (Ferrara, 2003). 
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1.3. VEGF RECEPTORS 
 
Angiogenesis is controlled by paracrine signals and most of them are produced by the 
binding between small molecules (i.e. VEGF) and transmembrane receptor tyrosine 
kinase (RTK). The human VEGF protein binds with high affinity with two classes of 
receptor tyrosine kinase: a) flt-1 (fms-like tyrosine-kinase) is expressed on vascular 
endothelial cells, confirming the primary action of VEGF on vascular endothelium 
(Fong, 1995). b) KDR (kinase domain region) known also as flk-1 (fetal liver kinase-1) is 
identified on endothelial cells, monocytes and tumor cells (Shalaby, 1995) showing 
affinity for VEGF165 but not VEGF121. As members of the RTK family, both the 
receptors are organized into three domains: an extracellular domain consisting of 
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seven extracellular region similar to immunoglobulins (Ig-like), a transmembrane and 
an intracellular domain responsible of the intracellular tyrosine kinase activity. Flt-4 is 
also a member of the RTK family and binds VEGF-C. The interaction with both 
receptors (flt-1 and KDR) is essential to induce the full spectrum of VEGF biological 
activity. The cascade of events involved in the transduction signal induced by VEGF 
(which begins with the autophosphorylation and dimerization of the receptors upon 
interaction with the ligand), is 
followed by a succession of 
phosphorylations that leads to the 
activation of alternative pathways 
(i.e. Ras) (Grugel, 1995; Fong, 1995; 
Shalaby, 1995; Merenmies, 1997). VEGF 
shows different biological effects 
depending on the binding receptor; 
although flt-1 and KDR are highly homologous they activate distinct pathways sending 
different signals to the endothelial cells. Numerous experiments using cell lines 
transfected with flt-1 and KDR genes concluded that their expression is essential for 
most of the VEGF biological effects: while the interaction between VEGF and flk-
1/KDR is followed by proliferation of endothelial cells, no mitogenic effects were 
observed after VEGF bound with flt-1. Other studies showed that the interaction of 
VEGF with flt-1 activates phosphatidylinositol pathway and, for this reason, it may be 
involved in monocytes migration. The expression of high affinity VEGF receptors 
during the early stages of embryonic development (hemangioblasts), suggests a role 
in vasculogenesis and angiogenesis and is one of the first events of the differentiation 
of endothelial cells. It has been also reported how conditions of chronic oxygen 
deficits, in which angiogenesis is a more appropriate response, VEGF receptors are 
Olgasi,2008 
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increased and thus potentially facilitate VEGF action. Indeed, hypoxia increases 
VEGF binding sites in cultured bovine retinal endothelial cells and increased mRNA 
levels of both KDR/Flk and Fit in the lung of rats exposed to hypoxia. (Takagi, 1996.) 
 
 
 
1.4. REGULATION OF GENE EXPRESSION OF VEGF 
 
Several mechanisms are involved in the regulation VEGF gene regulation. An 
important role is played by tissue O2 tension, as evidenced by reversible mRNA levels 
of VEGF under hypoxic conditions in vivo and in vitro. The increased expression of 
VEGF mRNA is mainly mediated by the transcription factor HIF-1 (hipoxia-inducible 
factor 1), which binds to a recognition site in the promoter region of the VEGF gene. 
(Harris,2002 ) The hypoxic induction of VEGF expression is mediated through adenosine 
a2 receptors and consequent increase of intracellular cAMP through the activation of 
the translation related to c-src. Increased levels of VEGF mRNA in response to 
hypoxia is due to an increased stability of the mRNA by attachment of a protein 
induced by hypoxia at the 3 'non-coding mRNA. Is reported that the VEGF mRNA is 
regulated at the transcriptional and post-transcriptional level also by glucose deficit. 
Moreover, several cytokines are able to operate indirectly an up-regulation of VEGF 
mRNA, resulting in protein synthesis and secretion of vascular endothelial growth 
factor. Transcription Growth Factor-a (TGF-a), TGF-b, epidermal growth factor (EGF), 
the mediators of the inflammatory response such as interleukin (IL)-1b and 
prostaglandin E2 are able to induce the expression of VEGF, suggesting the latter's 
participation in inflammatory processes. It has been also reported that Insulin Growth 
Factor 1 (IGF-1), in addition to its proliferative effect, can induce the expression of 
VEGF by tumor cells. Activation of protein kinase C, protein kinase A, Ras oncogene 
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and overexpression of v-raf or v-src is also related to VEGF over expression (Rak, 
1995). Moreover the cell cycle regulatory proteins such as p53 and suppressor gene 
Von Hippel-Lindau (VHL) have been also described as VEGF up-regulatory factors. 
(Mukhopadhyay, 1997). The increased level of concentration of VEGF also leads to over-
expression of the receptors Flt-1and KDR on endothelial cells. Later, after the 
vascular development the expression of VEGF is reduced gradually (Penn, 2008). 
In the 1970s Judah Folkman stated that tumors were dipendent on blood vessels for 
their growth eh expansion (Folkman, 1971). This concept of angiogenesis is the 
formation of new blood vessels from pre-existing vessels. The 1980s saw the advent 
in several laboratories of a tumor-derived protein inducing angiogenesis, called 
vascular endothelial growth factor A (VEGFA) (Ferrara, 1989; Leung, 1989; Plouet, 1989), 
and one vascular permeability factor (VPF), which increased permeability (Keck, 1989; 
Senger, 1986). It was later revealed that these two proteins were one and the same, and 
was upregulated in all solid tumors acting via its receptors found mainly on endothelial 
cells in blood vessels (Rennel, 2009) 
 
 
 
 
1.5. VEGF, OXYGEN REACTIVE SPECIES (ROS) AND 
MICROVASCULAR PERMEABILITY 
 
VEGF greatly enhances microvascular permeability; however, the molecular 
mechanisms controlling VEGF-induced permeability remain unknown. Endothelial 
permeability is mediated by two pathways: the transcellular pathway and the 
paracellular pathway. In the transcellular pathway material passes through the cells, 
whereas in the paracellular pathway fluid and macromolecules pass between the 
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cells. The paracellular pathway is regulated by the properties of endothelial cell-cell 
junctions (Dejana, 2004; Muller, 2003; Vestweber, 2008). 
Treatment of microvascular endothelial cells with VEGF led to an increase in reactive 
oxygen species (ROS) production. Additionally, treatment with VEGF caused ROS-
dependent tyrosine phosphorylation of both vascular-endothelial (VE)-cadherin and β-
catenin (Monaghan-Benson, 2009). VE-cadherin is an endothelial cell-specific adhesion 
molecule that connects adjacent endothelial cells (Gotsch, 1997; Corada, 1999). Disruption 
of VE-cadherin is sufficient to disrupt intercellular junctions (Corada, 1999; Carmeliet, 1999; 
May, 2005) Additionally, VE-cadherin is required to prevent disassembly of blood vessel 
walls (May, 2005; Hordijk, 1999; Crosby, 2005) and to coordinate the passage of 
macromolecules through the endothelium (Fukuhara, 2005; Kooistra, 2005). Tyrosine 
phosphorylation may provide the regulatory link, as increased phosphorylation of 
cadherins and potential dissociation of the cadherin/catenin complex results in 
decreased cell-cell adhesion and increased permeability (Ozawa, 1998; Potter, 2005). 
Recent evidence has demonstrated that Rac1-induced reactive oxygen species (ROS) 
disrupt VE-cadherin based cell-cell adhesion (Van Wetering, 2002).  
The mechanisms by which ROS affect endothelial permeability have not been fully 
characterized. VEGF has been reported to induce NADPH oxidase activity and induce 
the formation of ROS (Abid, 2000 & 2001). 
In many cell types, including endothelial cells the major producer of ROS is NADPH 
oxidase (Babior, 2000). 
These data indicate that VEGF treatment leads to the production of ROS and that 
these ROS are required for the increase in microvascular permeability. 
Tyrosine phosphorylation of various adherens junction molecules in the endothelium is 
indicative of decreased junctional integrity (Volberg, 1992; Birchmeier, 1994). One of the 
major adhesion molecules of endothelial junctions is VE-cadherin. VEGF-induced 
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ROS production regulates the tyrosine phosphorylation of adherens junction proteins 
VE-cadherin, β-catenin, and p120-catenin and their association. VEGF has a well 
known and well studied role in angiogenesis. However, the molecular mechanisms 
that regulate VEGF-induced permeability in the microvasculature, the first described 
function of VEGF, remain incompletely understood (Senger, 1983; Senger, 1986). It was 
shown that VEGF regulates microvascular permeability through the activation of Rac1 
and the production of ROS. These molecules, in turn, regulate the tyrosine 
phosphorylation of adherens junction proteins VEcadherin and β-catenin, ultimately 
regulating junctional integrity (Monaghan-Benson, 2009). 
 
 
 
1.6. VEGF, IRON DEFICIENCY AND ANGIOGENESIS 
 
Cellular iron deficiency increased HIF-1a, VEGF, and angiogenesis, suggesting that 
systemic iron deficiency might play an important part in the tumor angiogenesis. Iron 
is an essential metal for all living organisms participating in cellular processes, such 
as DNA synthesis, enzyme functions, and oxygen transport. Cellular iron metabolism 
is homologous among most cell types; cellular iron homeostasis is primarily mediated 
by transferrin (Tf), transferrin receptor-1 (TfR1), and ferritin (Pantopoulos, 2004; Rouault, 
2006; Muckenthaler, 2008). Tf is an iron transport protein with two iron-binding sites and is 
mainly found in the bloodstream, from which it circulates and delivers iron throughout 
the body. TfR1 is a ubiquitous membrane protein forming a complex with Tf, which 
initiates membrane endocytosis and serves as a major cellular iron uptake pathway. 
Excess iron within cells is stored in ferritin. When cells are iron deficient, iron 
regulatory proteins (IRPs) bind to iron responsive elements (IRE) in the 3′ 
untranslated region (UTR) of TfR1 mRNA as well as 5′ UTR of ferritin mRNA. The IRP 
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binding to 3′-UTR results in TfR1 upregulation and increased iron uptake, but its 
binding to 5′-UTR of ferritin leads to its downregulation and decreased iron storage 
(Rouault, 2006; Muckenthaler, 2008; Recalcati, 2010). 
HIF-1a is a critical transcription factor for the regulation of vascular endothelial growth 
factor (VEGF), a potent inducer of tumor angiogenesis and metastasis (Bertout, 2008). 
However, direct evidence of iron deficiency on VEGF is lacking and the effect of iron 
deficiency on tumor angiogenesis has not yet been studied. 
To further associate iron deficiency with HIF-1a, VEGF, and angiogenesis, using iron 
supplementation causes a destabilization of HIF-1a , a result  which supports the idea 
that iron deficiency contributes to HIF-1a induction and stabilization. Further 
confirmation, the effects of iron supplementation also extended beyond cellular HIF 
stabilization and into downstream HIF signaling, which lead to a lower level of VEGF 
and a decline in the in vitro angiogenesis . 
 
 
 
1.7. FUNCTION OF VEGF IN TUMORS 
 
VEGF plays a crucial role in growth of most primary tumors and the subsequent 
process of metastasis. In many human tumors is observed an up-regulation of VEGF 
and its mRNA (mRNA and VEGF receptor), an increase in the levels of VEGF found 
both within the tumor into the circulation. Tumor growth requires vascularization that is 
mediated by VEGF. The VEGF released from the tumor acts at the level of VEGF 
receptors present on endothelial cells and activate angiogenesis. Thus, the VEGF 
stimulates the formation of a new and immature blood supply that has structural and 
functional abnormalities. The production of VEGF by the tumor creates a positive 
feedback by which the angiogenesis induced by VEGF allows further tumor growth. 
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As a result of this fast-growing cancer exceeds the limits of its blood supply and the 
contribution of oxygen and nutrients becomes inadequate, resulting in areas of 
hypoxia.  
In a rapidly growing tumor, O2 demand increases and O2 delivery decreases, 
primarily because of: A) insufficient blood supply (at least to some tumor areas) 
and B) increasing diffusion distances between the blood vessels and the O2-
consuming cells (Vaupel, 1989; Giordano, 2001). This leads to hypoxia in the expanding 
tumor mass, triggering events that stimulate angiogenesis in an effort to ameliorate 
the hypoxic condition. In tumor tissue, the ability to induce angiogenesis is associated 
with the development of an aggressive phenotype, as metastatic cells have more 
opportunity to enter the circulation in a well-vascularized tumor and thereby escape 
their hostile environment (Goonewardene, 2002; Hanahan, 1996). Production of VEGF is 
driven by hypoxia via transcription activation of the VEGF gene by HIF-1 (Forsythe, 
1996). The basic importance of HIF-1 in the angiogenic process has been 
demonstrated in several experimental and clinical studies (Maxwell, 2002). Carmeliet et 
al. reported a reduced hypoxic induction of VEGF in vitro in mouse embryonic stem 
cells with inactivated HIF-1α genes (Carmeliet, 1998). 
In vivo studies, found that HIF-1α–/– embryonic stem-cell-derived tumors had fewer 
blood vessels and impaired hemodynamics within the tumor mass, and further, that 
HIF-1α knockout mice died in utero with a complete lack of cephalic vasculature as a 
consequence of disrupted angiogenesis (Ryan, 1998 & 2000). Additionally, VEGF has 
been shown to stimulate migration of macrophages by activation of the VEGF receptor 
(Flt-1). Macrophages produce several angiogenic factors, including VEGF and tumor 
necrosis factor alpha (TNF-α) (Leibovich, 1987; Leek, 2000). At the clinical level, the results 
of the majority of over a dozen studies comprising more than 3,500 patients generally 
speak in favor of an independent prognostic impact of VEGF expression regarding 
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relapse-free and overall survival. Additionally, VEGF expression may be predictive of 
the anatomical site of first recurrence (Goonewardene, 2002). 
In addition to VEGF, other angiogenesis-related gene products and receptors are 
regulated by HIF-1, including PDGF-B, VEGFR-1, endothelin-1, inducible nitric oxide 
synthetase (iNOS), monocyte chemotactic protein, adrenomedullin, and EGF. Several 
of these, including iNOS, endothelin-1, heme oxygenase 1, and adrenomedullin, have 
been shown to play roles in the regulation of local blood flow by the modulation of 
vascular tone (Wenger, 2002). Thus, it appears that HIF-1 not only mediates 
angiogenesis by VEGF induction but also influences tumor blood flow by more 
complex mechanisms involving target genes playing a role in vessel tone. 
Yet another mechanism for stimulation of tumor angiogenesis is induction of HIF-1 
and VEGF subsequent to somatic mutation. One example of this is seen in the loss of 
p53 tumor-suppressor activity either by direct mutational inactivation or by 
overexpression of mouse double minute, a ubiquitin protein ligase involved in the 
degradation of p53. Loss of p53 activity results in decreased hypoxia-mediated 
apoptosis, possibly increased HIF-1α expression (Ravi, 2000), and a subsequent 
increase in HIF-1-mediated transactivation of VEGF and other target genes, thereby 
facilitating tumor angiogenesis.  
Angiogenesis, stimulated by VEGF, promotes the contact of tumor cells with blood 
vessels, providing a way for cells to invade the vessels themselves, Excessive 
production of VEGF leads to the formation of very permeable immature vessels, which 
will facilitate the invasion. VEGF is also involved in lymphangiogenesis. Stimulating 
the formation of giant lymphatic vessels, VEGF provides another possible route of 
metastatic spread. In humans, VEGF is overexpressed by a wide variety of different 
malignant tumours. Increased VEGF concentrations in the serum and plasma of 
patients indicate a poor prognosis for numerous tumor types and the magnitude of 
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VEGF concentration reflects tumour burden, response to therapy, and disease 
progression. Recently, VEGF has been shown to inhibit cells of dendritic cell lineage 
by impairing their antigen-presenting ability and limiting tumor cell detection by the 
immune system, thus enhancing metastasis. 
 
 
 
 
1.8. VEGF IN CANINE PATIENTS 
 
In dogs were identified similar VEGF isoforms described in humans differing due to 
the absence of a residues at the N-terminal region. In dogs, as in most other 
mammals, it should then use the following terminology: VEGF164 and VEGF120 (soluble 
isoforms) and VEGF205, VEGF144 and VEGF188 (soluble isoforms, linked to the matrix 
extracellular). Between man and dog there is a complete homologue amino acid 
sequence involved in receptor development. This correspondence implies that the two 
proteins (human and canine) have the same binding properties and explains ability of 
canine VEGF164 to activate human endothelial cells in same degree of VEGF165; 
VEGFR-1 overexpression (together with that of VEGF) has been highlighted in several 
canine cancers (Scheidegger, 1999). Although VEGF expression has been documented 
in dogs with several solid tumors (Barbara kaser hotz) its role in canine malignancies 
is not well defined. In 2 recent studies (Wergin, 2004a & 2004b) concentrations of VEGF in 
dogs with naturally occurring neoplasia were found to be highest with malignant 
melanoma. These investigators also identified a significant difference among types of 
tumors and plasma VEGF concentrations (Wergin 2004b). High concentrations of VEGF 
were thought to be associated with the aggressiveness of the tumor but were not 
associated with tumor stage or tumor volume (Wergin 2004a). High concentrations of 
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VEGF were found in this study and were comparable to concentrations observed in 
the carcinoma category of tumors in the study (Wergin 2004a). VEGF serum 
concentration has been also investigated in healty and noneoplastic dogs and were 
found to be detectable in less than 10% of these patients whereas more than 40% of 
tumor dogs had detectable VEGF serum concentration (Troy, 2006). A recent study 
showed that canine patients with a serum VEGF level < 63 pg/mL had a doubled 
median overall survival if compared to those with a VEGF > 63 pg/mL (Marchetti, 2011).  
 
 
 
1.8.1. VEGF IN MAST CELL TUMOURS (MCT) 
 
Mast cell tumors (MCT) are frequent neoplasms in dogs (Macy, 1985; London, 2003; 
Misdorp, 2004). These tumours are often detected in the skin, but can also develop in 
and metastasize into other (visceral) organs (Macy, 1985; London and Seguin, 2003; Misdorp, 
2004). The biological behaviour of canine mastocytomas varies considerably among 
patients (Rogers, 1996; Govier, 2003; London, 2003; Cahalane, 2004; Misdorp, 2004). Metastatic 
and progressive MCT usually exhibit a poor response to conventional antineoplastic 
drugs and thus have an unfavourable prognosis (Rogers, 1996; Govier, 2003; London, 2003; 
Cahalane, 2004; Misdorp, 2004). Aggressive MCT tumours usually exhibit a high grade 
histology (Patnaik, 1984). The expression of VEGF and VEGF receptors in neoplastic 
canine MC is poorly understood. Thus, whereas it is well known that normal mast cells 
in various species can express and release VEGF under certain circumstances (cell 
activation) and that mast cell-derived VEGF is involved in the regulation of wound 
healing and angiogenesis (Boesiger, 1998; Artuc, 1999; Szukiewicz, 2005), little is known so 
far about the expression of VEGF in neoplastic MC. Wimzal and colleagues have 
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recently shown that neoplastic human MCs in patients with systemic mastocytosis 
express detectable amounts of VEGF (Wimazal, 2002). Several studies have shown that 
normal mast cells can express and release VEGF, and that mast cell-derived VEGF is 
involved in the regulation of angiogenesis (Boesiger, 1998; Artuc, 1999; Szukiewicz, 2005). 
The expression of VEGF and of VEGF receptors in primary MCT in dogs and in 
canine mastocytoma cell line C2 has been investigated to determine whether VEGF 
acts as an autocrine growth regulator in neoplastic MCs (Rebuzzi, 2007) and although 
neoplastic cells often utilize VEGF as an autocrine growth factor (Giles, 2001; Gerber, 
2003; Shinkaruk, 2003), in contrast to other neoplasms, mastocytoma cells may 
apparently do not utilize VEGF as an autocrine growth regulator (Rebuzzi, 2007). Only 
one study investigated in deep the relationship between cytosol and circulating VEGF 
levels, microvascular density (MVD) and mast cell density (MCD) in regulating tumour 
angiogenesis and progression of canine MCT (Patruno, 2009). It was noticed that serum 
VEGF may be an inaccurate indicator of circulating VEGF due to its release during 
sampling as no correlations between serum VEGF and MVD and between serum 
VEGF and malignancy grade of MCTs was found.  
VEGF levels were found to be low in platelet poor plasma (P-PP) blood fraction 
suggesting that VEGF from serum samples is derived from platelets during the 
coagulation process as reported in human MCs (Verheul, 1997). Accordingly, VEGF 
levels in the P-PP could reflect the excess of circulating VEGF to the steady state with 
platelets levels without any biological clinical significance. VEGF levels from both 
cytosol and P-APR were higher than in P-PP and showed a statistically significant 
increase in G3 tumours when compared to G1 and G2. This study showed also that 
MCs of canine MCTs were the main source of circulating VEGF protein, which may be 
released by degranulation and then stored in platelets. In fact, was demonstrated that 
MCs in G3 MCTs subgroup contained few or no cytoplasmatic granules and this 
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parameter correlated with high MVD, high VEGF level from cytosol and high VEGF 
level from P-APR. On the contrary, MCs in G1 or G2 CMCTs were less degranulated, 
showing more methacromatic granules in their cytoplasm and these data correlated 
with low angiogenesis biblio. 
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2. OXIDATIVE STRESS AND ANTIOXIDANTS 
 
2.1. OXIDATIVE STRESS AND ANTIOXIDANTS 
 
In the last two decades there has been an explosive interest in the role of oxygen-
free radicals, more generally known as “reactive oxygen species,” (ROS) and of 
“reactive nitrogen species” (RNS) in experimental and clinical medicine (Halliwell, 
1999). ROS and RNS: (I) are generated during irradiation by UV light, by X-rays 
and by gamma rays; (II) are products of metal-catalyzed reactions; (III) are present 
as pollutants in the atmosphere; (IV) are produced by neutrophils and 
macrophages during inflammation; (V) are by-products of mitochondria-catalyzed 
electron transport reactions and other mechanisms (Cadenas, 1989). ROS/RNS are 
known to play a dual role in biological systems, since they can be either harmful or 
beneficial to living systems (Valko, 2004). Beneficial effects of ROS involve 
physiological roles in cellular responses to anoxia, as for example in defence 
against infectious agents and in the function of a number of cellular signalling 
systems. One further beneficial example of ROS at low concentrations is the 
induction of a mitogenic response. In contrast, at high concentrations, ROS can be 
important mediators of damage to cell structures, including lipids and membranes, 
proteins and nucleic acids (termed oxidative stress) (Poli, 2004). The harmful effects 
of ROS are balanced by the antioxidant action of non-enzymatic antioxidants in 
addition to antioxidant enzymes (Halliwell, 1996). Despite the presence of the cell’s 
antioxidant defence system to counteract oxidative damage from ROS, oxidative 
damage accumulates during the life cycle, and radical-related damage to DNA, to 
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proteins  and to lipids has been proposed to play a key role in the development of 
age-dependent diseases such as cancer, arteriosclerosis, arthritis, 
neurodegenerative disorders and other conditions (Halliwell, 1999).  
Free radicals can be defined as molecules or molecular fragments containing one 
or more unpaired electrons. The presence of unpaired electrons usually confers a 
considerable degree of reactivity upon a free radical. Those radicals derived from 
oxygen represent the most important class of such species generated in living 
systems (Valko, 2004). ROS can be produced from both endogenous and 
exogenous substances. Potential endogenous sources include mitochondria, 
cytochrome P450 metabolism, peroxisomes, and inflammatory cell activation 
(Inoue, 2003). Mitochondria have long been known to generate significant quantities 
of hydrogen peroxide. The hydrogen peroxide molecule does not contain an 
unpaired electron and thus is not a radical species. Under physiological conditions, 
the production of hydrogen peroxide is estimated to account for about ?2% of the 
total oxygen uptake by the organism. However, it is difficult to detect the 
occurrence of the superoxide radical in intact mitochondria, most probably in 
consequence of the presence of high SOD activity therein. Generation of the 
superoxide radical by mitochondria was first reported more than three decades 
ago (Loeschen, 1971). After the determination of the ratios of the mitochondrial 
generation of superoxide to that of hydrogen peroxide, the former was considered 
as the stoichiometric precursor for the latter. Ubisemiquinone has been proposed 
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as the main reductant of oxygen in mitochondrial membranes (Inoue, 2003). 
Mitochondria generate approximately 2–3 nmol of superoxide/min per mg of 
protein, the ubiquitous presence of which indicates it to be the most important 
physiological source of this radical in living organisms (Inoue, 2003). Since 
mitochondria are the major site of free radical generation, they are highly enriched 
with antioxidants including GSH and enzymes, such as superoxide dismutase 
(SOD) and glutathione peroxidase (GPx), which are present on both sides of their 
membranes in order to minimise oxidative stress in the organelle (Cadenas, 2000). 
Superoxide radicals formed on both sides of mitochondrial inner membranes are 
efficiently detoxified initially to hydrogen peroxide and then to water by Cu, Zn-
SOD (SOD1, localised in the intermembrane space) and Mn-SOD (SOD2, 
localised in the matrix). Besides mitochondria, there are other cellular sources of 
superoxide radical, for example xanthine oxidase (XO), a highly versatile enzyme 
that is widely distributed among species (from bacteria to man) and within the 
various tissues of mammals (Li, 2002). Xanthine oxidase is an important source of 
oxygen-free radicals. It is a member of a group of enzymes known as molybdenum 
iron–sulphur flavin hydroxylases and catalyzes the hydroxylation of purines. In 
particular, XO catalyzes the reaction of hypoxanthine to xanthine and xanthine to 
uric acid. In both steps, molecular oxygen is reduced, forming the superoxide 
anion in the first step and hydrogen peroxide in the second (Valko, 2004). Additional 
endogenous sources of cellular reactive oxygen species are neutrophils, 
eosinophils and macrophages. Activated macrophages initiate an increase in 
oxygen uptake that gives rise to a variety of reactive oxygen species, including 
superoxide anion, nitric oxide and hydrogen peroxide (Conner, 1996). Cytochrome 
P450 has also been proposed as a source of reactive oxygen species. Through 
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the induction of cytochrome P450 enzymes, the possibility for the production of 
reactive oxygen species, in particular, superoxide anion and hydrogen peroxide, 
emerges following the breakdown or uncoupling of the P450 catalytic cycle. In 
addition, microsomes and peroxisomes are sources of ROS. Microsomes are 
responsible for the 80% H2O2 concentration produced in vivo at hyperoxia sites 
(Gupta, 1997). Peroxisomes are known to produce H2O2, but not O2•−, under 
physiologic conditions. Although the liver is the primary organ where peroxisomal 
contribution to the overall H2O2 production is significant, other organs that contain 
peroxisomes are also exposed to these H2O2-generating mechanisms. 
Peroxisomal oxidation of fatty acids has recently been recognised as a potentially 
important source of H2O2 production as a result of prolonged starvation. The 
release of the biologically active molecules such as cytokines and others, from 
activated Kupffer cells (the resident macrophage of the liver) has been implicated 
in hepatotoxicological and hepatocarcinogenic events. Recent results indicate that 
there is a close link between products released form activated Kupffer cells and 
the tumour promotion stage of the carcinogenesis process (Klaunig, 2004). Reactive 
oxygen species can be produced by a host of exogenous processes. 
Environmental agents including non-genotoxic carcinogens can directly generate 
or indirectly induce reactive oxygen species in cells. The induction of oxidative 
stress and damage has been observed following exposure to various xenobiotics. 
These involve chlorinated compounds, metal (redox and non-redox) ions, radiation 
and barbiturates. For example 2-butoxyethanol is known to produce ROS 
indirectly, which causes cancer in mice (Klaunig, 1997).  
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2.2. OXIDATIVE DAMAGE TO BIOMOLECULES 
 
Reactive oxygen species are formed through a variety of events and pathways. It 
has been estimated that one human cell is exposed to approximately 1.5×105 
oxidative hits a day from hydroxyl radicals and other such reactive species 
(Beckman, 1997). The hydroxyl radical is known to react with all components of the 
DNA molecule: damaging both the purine and pyrimidine bases and also the 
deoxyribose backbone (Dizdaroglu, 2002). Permanent modification of genetic 
material resulting from these “oxidative damage” incidents represents the first step 
involved in mutagenesis, carcinogenesis and ageing. In fact, as is well 
established, in various cancer tissues free radical-mediated DNA damage has 
occurred. To date, more than 100 products have been identified from the oxidation 
of DNA. ROS-induced DNA damage involves single- or doublestranded DNA 
breaks, purine, pyrimidine, or deoxyribose modifications, and DNA cross-links. 
DNA damage can result either in arrest or induction of transcription, induction of 
signal transduction pathways, replication errors and genomic instability, all of 
which are associated with carcinogenesis (Marnett, 2000; Cooke, 2003). The hydroxyl 
radical is able to add to double bonds of DNA bases at a second-order rate 
constant in the range of (3–10)×109M−1 s−1 and it abstracts an H-atom from the 
methyl group of thymine and each of the five carbon atoms of 2’ deoxyribose at a 
rate constant of approximately 2×109M−1 s−1 (Dizdaroglu, 2002). While OH-adduct 
radicals of DNA bases are generated via an addition reaction, the allylic radical 
derived from thymine and carbon-centred sugar radicals arise by abstraction 
reactions (Dizdaroglu, 2002). Further reactions of base and sugar radicals generate a 
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variety of modified bases and sugars, base-free sites, strand breaks and DNA–
protein cross-links. The presence of 8-OH-G in human urine was first reported by 
Ames and co-workers (Shigenaga, 1989). 
 
Shigenaga,1989 
This oxidised DNA product is important because it is both relatively easily formed 
and is mutagenic and carcinogenic. It is a good biomarker of oxidative stress of an 
organism and a potential biomarker of carcinogenesis. We note that 8-
hydroxyguanine undergoes keto-enol tautomerism and therefore 8-OH-G is often 
called 8-oxoguanine or 8-oxo-G, however, 8-oxo-G and 8-OH-G are equivalent. 
This base modification occurs in approximately one in 105 guanidine residues in a 
normal human cell. Ionising radiation, a carcinogenic and exogenous source of 
ROS, induced both urinary and leukocyte biomarkers of oxidative DNA damage 
(Halliwell, 1999). Tobacco smoking, another carcinogenic source of ROS, increases 
the oxidative DNA damage rate by 35–50%, as estimated from the urinary 
excretion of 8-oxo-G, and the level of 8-oxo-G in leukocytes by 20–50%. 
Measurements demonstrated that factors such as hard physical labour, day–night 
shift work, smoking and low meat intake significantly increased the 8-oxo-G level, 
while moderate physical exercise, such as sports reduced its level (Kasai, 2001). 
The potential connection between 8-nitroguanine and the process of 
carcinogenesis is unknown. In addition to the extensive studies devoted to the role 
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of oxidative nuclear DNA damage in neoplasia, there exists evidence about the 
involvement of the mitochondrial oxidative DNA damage in the carcinogenesis 
process (Inoue, 2003). Mutations and altered expression in mitochondrial genes 
encoding for complexes I, III, IV and V, and in the hypervariable regions of 
mitochondrial DNA, have been identified in various human cancers. The following 
points account for the fact that mitochondrial DNA is more susceptible to oxidation 
than nuclear DNA (Inoue, 2003): (I) under physiological conditions, the mitochondria 
convert ?5% of oxygen consumed into superoxide anion and subsequently 
hydrogen peroxide; (II) mitochondrial DNA repair capacity is limited, since they 
lack entirely the feature of nucleotide excision repair; (III) mitochondrial DNA is not 
protected by histones. Hydrogen peroxide and other reactive oxygen species have 
been implicated in the activation of nuclear genes that are involved in 
mitochondrial biogenesis, transcription, and replication of the mitochondrial 
genome. Although the region of tumour cells that possess mutated mitochondrial 
DNA and the extent to which mitochondrial DNA alterations participate in the 
cancer process have not been satisfactorily established, a significant amount of 
information supporting the involvement of the mitochondria in carcinogenesis 
exists (Penta, 2001). This connection supports the fact that fragments of 
mitochondrial DNA have been found to be inserted into nuclear DNA, suggesting a 
possible mechanism for activation of oncogenes. In conclusion, as observed with 
oxidative genomic DNA modification, oxidative damage and the induction of 
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mutation in mitochondrial DNA may participate at multiple stages of the process of 
carcinogenesis, involving mitochondria-derived ROS, induction of mutations in 
mitochondrial genes, and possibly the insertion of mitochondrial genes into nuclear 
DNA (Penta, 2001). As described above, oxygen radicals may induce a number of 
DNA base alterations that can lead to mutagenesis. However, there are specific 
and general repair mechanisms that can repair DNA base modifications (Evans, 
2004; Kasai, 2002). Off interest is the fact, that the efficiency of repair mechanisms 
may be enhanced following exposure to reactive oxygen species because 
expression of many DNA repair enzymes is upregulated following oxidative stress. 
Since in nuclear DNA, ?90% of oxidised bases are repaired by single nucleotide 
repair mechanisms and the remaining 10% by long-patch base excision repair, the 
single nucleotide base excision repair is the primary pathway for repair of 8-OH-G. 
The first evidence of a repair mechanism for the 8-OH-G lesion was observed in 
irradiated mouse liver, where levels of this lesion were found to decrease with time 
(Kasai, 2002).  
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2.3. OXIDATIVE STRESS, CELL SIGNALLING AND CANCER 
 
Cells communicate with each other and respond to extracellular stimuli through 
biological mechanisms called cell signalling or signal transduction (Poli, 2004; 
Thannickal, 2000). Signal transduction is a process enabling information to be 
transmitted from the outside of a cell to various functional elements inside the cell. 
Signal transduction is triggered by extracellular signals such as hormones, growth 
factors, cytokines and neurotransmitters (Hensley, 2000). Signals sent to the 
transcription machinery responsible for expression of certain genes are normally 
transmitted to the cell nucleus by a class of proteins called transcription factors. By 
binding to specific DNA sequences, these factors regulate the activity of RNA 
polymerase II. These signal transduction processes can induce various biological 
activities, such as muscle contraction, gene expression, cell growth and nerve 
transmission (Sah, 2000). While ROS are predominantly implicated in causing cell 
damage, they also play a major physiological role in several aspects of 
intracellular signalling and regulation (Palmer, 1997). It has been clearly 
demonstrated that ROS interfere with the expression of a number of genes and 
signal transduction pathways (Thannickal, 2000). Because ROS are oxidants by 
nature, they influence the redox status and may, according to their concentration, 
cause either a positive response (cell proliferation) or a negative cell response 
(growth arrest or cell death). As already mentioned above, while high 
concentrations of ROS cause cell death or even necrosis, the effects of ROS on 
cell proliferation occurred exclusively at low or transient concentrations of radicals. 
Low concentrations of superoxide radical and hydrogen peroxide in fact stimulate 
  31
CHAPTER 2 OXIDATIVE STRESS AND ANTIOXIDANTS 
 
 
 
 
proliferation and enhanced survival in a wide variety of cell types.ROS can thus 
play a very important physiological role as secondary messengers (Lowenstein, 
1994). Other examples include regulation of the cytosolic calcium concentration 
(which itself regulates the above-mentioned biological activities), regulation of 
protein phosphorylation, and activation of certain transcription factors such as NF-
kB and the AP-1 family factors (Storz, 2005). 
 
Valko,2006 
ROS and metal ions primarily inhibit phosphorserine/threonine-, phosphotyrosine- 
and phospholipidphosphatases, most probably by interacting with sulphydryl 
groups on their cystein residues, which are oxidised to form either intramolecular 
or intermolecular disulphide bonds (Valko, 2004; Thannickal, 2000). These structural 
changes alter protein conformation which leads to the upregulation of several 
signalling cascades, most importantly growth factor kinase-, src/Abl kinase-, 
MAPK- and PI3-kinase-dependent signalling pathways. These signalling cascades 
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lead to the activation of several redox-regulated transcription factors (AP-1, NF-kB, 
p53, HIF-1, NFAT). 
In veterinary oncology oxidant and antioxidant profile has not been evaluated so 
far, and few reports investigated mammary tumours (Szczubiał, 2004; 
Kumaraguruparan, 2005) and lymphomas (Vajdovich, 2005; Winter, 2009). In mammary 
tumours was observed an enhanced lipid peroxidation, attributed to 
overproduction of ROS, followed by an increase of the antioxidant barrier. Authors 
suggested that an increased lipid peroxidation and host antioxidant defences 
associated with the development of canine mammary tumours may offer a 
selective growth advantage to tumours cells over their surrounding normal 
counterparts.  
In canine lymphoma patients a decrease in vitamin E secondary to lymphoma 
development was observed, suggesting an imbalance between ROS production 
and antioxidant protection. Glutathione Peroxidase (GSHPx) was found to be 
increased in one study (Winter, 2009) according to the fact that Glutathione is a 
principal cellular antioxidant and serves to regenerate oxidized vitamins C and E to 
their reduced and bioactive forms. On the other hand this is in contrast to the data 
reported by Vajdovich and collegues (Vajdovich, 2005) were GSHPx was found to be 
reduced, however this conflict could be related to differences in WHO classification 
and substage (including inclusion of more dogs with advanced disease in the 
study of Winter and collegues) or different immunophenotypes.  
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2.3.1. CYTOKINES AND GROWTH FACTORS SIGNALLING 
 
A variety of cytokines and growth factors that bind to receptors of different classes 
have been reported to generate ROS in nonphagocytic cells. Growth factor 
receptors are tyrosine kinases (RTKs) that play a key role in the transmission of 
information from outside the cell into the cytoplasm and the nucleus (Neufeld, 1999). 
The information is transmitted via the activation of mitogen-activated protein 
kinases (MAPKs) signalling pathways (Hazzalin, 2002). ROS production as a result 
of activated growth factor receptor signalling includes epidermal growth factor 
(EGF) receptor (Bae, 1997), platelet-derived growth factor (PDGF) receptor (Catarzi, 
2002), vascular endothelial growth factor (VEGF) (Neufeld, 1999). Further examples 
involve cytokine receptors (TNF-a and IFN-y) or interleukin receptors (IL-1b) 
(Sundaresan, 1996). Cytokines receptors fall into a large and heterogenous group of 
receptors that lack intrinsic kinase activity and are most directly linked to ion 
channels or G proteins. Cytokines such as TNF-a, IL-1 and interferon (IFN-y) were 
among those first reported to generate ROS in nonphagocytic cells (Chapple, 1997). 
It is generally accepted that ROS generated by these ligand/receptor-initiated 
pathways can function as true second messengers and mediate important cellular 
functions such as proliferation and programmed cell death. Abnormalities in 
growth factor receptor functioning are closely associated with the development of 
many cancers (Drevs, 2003). Several growth factor receptors (EGF, PDGF, VEGF) 
are affected by carcinogenic metals such as nickel, arsenic, cobalt and beryllium 
(Simeonova, 2002). The EGF receptor is associated with cell proliferation in normal 
cells. Nickel has been found to increase expression of the EGF receptors and 
overexpression of the EGF receptor has been observed in lung and urinary 
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cancers (Kim, 2001). Exogenous oxidative stress appears to stimulated secretion of 
heparin-binding EGF. VEGF is involved in proliferation and angiogenesis and also 
is induced by carcinogenic metals (Co, Ni and As) and hypoxia. Arsenic-induced 
VEGF expression appears to be associated with p38 (Leonard, 2004). Activation of 
both EGF and VEGF results in increases in cellular Ca(II). A similar effect was 
observed in a various cell types following treatment with Ni(II), Cd(II) and Be(II) 
compounds. The VEGF is probably most strongly activated by hydrogen peroxide. 
The PDGF is found in endothelial cells, fibroblasts and mesenchymal cells; the 
overexpression of PDGF has been found in lung and prostate cancers.  
 
 
2.4. ANTIOXIDANT DEFENCE MECHANISMS IN CARCINOGENESIS 
 
The effect of reactive oxygen and nitrogen species is balanced by the antioxidant 
action of non-enzymatic antioxidants, as well as by antioxidant enzymes. Such 
antioxidant defences are extremely important as they represent the direct removal 
of free radicals (pro-oxidants), thus providing maximal protection for biological 
sites. A good antioxidant should: (I) specifically quench free radicals; (II) chelate 
redox metals; (III) interact with (regenerate) other antioxidants within the 
“antioxidant network”; (IV) have a positive effect on gene expression; (V) be 
readily absorbed; (VI) have a concentration in tissues and biofluids at a 
physiologically relevant level; (VII) work in both the aqueous and/or membrane 
domains. The most efficient enzymatic antioxidants involve superoxide dismutase, 
catalase and glutathione peroxidase (Mates, 1999). Non-enzymatic antioxidants 
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involve Vitamin C, Vitamin E, carotenoids, thiol antioxidants (glutathione, 
thioredoxin and lipoic acid), natural flavonoids, a hormonal product of the pineal 
gland, melatonin and other compounds (McCall, 1999). Some antioxidants act in a 
hydrophilic environment, others in a hydrophobic environment, and some act in 
both environments of the cell. For example, Vitamin C reacts with superoxide in 
the aqueous phase while Vitamin E does so in the lipophilic phase. In contrast, a-
lipoic acid is both water and fat soluble and therefore can operate both in cellular 
membranes and in cytosol. Certain antioxidants are able to regenerate other 
antioxidants and thus restore their original function. This process is called an 
“antioxidant network” (Sies, 2005). The redox cycles of vitamins E and C form such 
an antioxidant network. The capacity to regenerate one antioxidant by another is 
driven by the redox potentials of the [Red/Ox] couple. There is a link between 
increased levels of ROS and disturbed activities of enzymatic and non-enzymatic 
antioxidants in tumour cells.  
 
2.4.1. VITAMIN E 
 
Vitamin E is a fat-soluble vitamin that exists in eight different forms. α-Tocopherol 
is the most active form of vitamin E in humans and is a powerful biological 
antioxidant which is considered to be the major membranebound antioxidant 
employed by the cell (eight chemically distinct analogues are now known, 
consisting of alpha (α), beta (β), gamma (γ) and delta (δ)-tocopherols (TP) and 
alpha, beta, gamma and delta-tocotrienols (T3); all of themare referred to as 
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vitamin E. The tocopherols are saturated forms of vitamin E, whereas the 
tocotrienols are unsaturated and possess an isoprenoid side chain. (Burton, 1989). 
Its main antioxidant function is protection 
against lipid peroxidation (ascorbic acid is 
regarded as the major aqueous phase 
antioxidant) (Prior, 2000). Recent evidence 
suggests that α-tocopherol and ascorbic 
acid function together in a cyclic-type of 
process. During the antioxidant reaction, α-
tocopherol is converted to α-tocopherol 
radical by the donation of labile hydrogen to 
a lipid or lipid peroxyl radical. The α-
tocopherol radical can thus be reduced to 
the original α-tocopherol form by ascorbic 
acid (Kojo, 2004). Several epidemiological trials reported the effect of the intake of 
Vitamin E supplements. It has been demonstrated that the intake of Vitamin E [200 
IU (international units)/day] reduced the incidence of coloretal cancer by triggered 
apoptosis of cancer cells by inducing p21wafi/cip1, a powerful cell cycle inhibitor 
(White, 1997). Generally, the protective effect of Vitamin E is a result of the inhibition 
of free radical formation and activation of endonucleases. Other study reported 
negative results for Vitamin E in combination with Vitamin C and betacarotene to 
prevent colorectal cancer adenoma over a period of 4 years (Greenberg, 1994). Since 
Vitamin C regenerates Vitamin E, it has been proposed that addition of Vitamin E 
hinders the protective effect of Vitamin C against oxidative damage (Dreher, 1996). 
Aggarwal,2010 
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Of great surprise was a recent trial which revealed that daily Vitamin E doses of 
400 IU or more can increase the risk of death and should be avoided (Miller, 2005). 
According to the analysis, there is no increased risk of death with a dose of 200 IU 
per day or less, and there may even be some benefit. 
 
 
2.4.1.1. VITAMIN E IN ANIMAL MODELS 
 
In animals Tocotrienols exhibit activity in different models of both prevention and 
treatment of cancer. Perhaps the first report about the therapeutic potential of 
tocotrienols for cancer in animal models was by Kato et al., who in 1985 showed 
that tumor-bearing rats administered with tocotrienols had an extended life span 
(Kato, 1985). Komiyama et al. observed antitumor activity when tocotrienols were 
administered intraperitoneally to mice with established murine Meth A 
fibrosarcoma. They showed that tocotrienols were more effective than α-
tocopherol, and among the tocotrienols, γ-tocotrienol was more effective than α-
tocotrienol as an antitumor agent (Komiyama, 1989). They also showed that 
tocotrienols are better antioxidants than tocopherols. The growth of highly 
metastatic B16 melanoma in female mice was inhibited by tocotrienols, and δ-
tocotrienol was more active than γ-tocotrienol in this setting (HE, 1997). In mice 
implanted with hepatoma, both γ-tocotrienol and δ-tocotrienol delayed tumor 
growth, and when examined for levels of tocotrienols, the tumors contained a 
specific accumulation of these analogues (Hiura, 2009). The antitumor effects of 
tocotrienols appear to be mediated in part through their ability to suppress 
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angiogenesis (Nakagawa, 2007). Suppression of angiogenesis is mediated through 
reduction in serum levels of VEGF and inhibition of the PI3K–AKT pathway. The 
inhibition of HMG-CoA reductase and the consequent decrease in serum 
cholesterol level has been linked with the tumor-suppressive action of tocotrienols 
(Elson, 1995). Tocotrienols have also been shown to enhance the antitumor effects 
of other agents. In one study, δ-tocotrienol was reported to enhance the growth-
suppressive effects of lovastatin in the B16 melanoma model in mice (McAnally, 
2007). Γ-Tocotrienol preferentially sensitized human prostate cancer in nude mice 
to radiation (Kumar, 2006). Besides antitumor effects against established tumors, 
tocotrienols have also been shown to be effective in cancer prevention models. 
Sundram et al. showed that palm oil, one of the richest dietary sources of 
tocotrienols, is effective in preventing 7,12-dimethylbenz[α]anthracene (DMBA)-
induced mammary carcinogenesis in rats, but corn oil and soybean oil, which 
contain tocopherols but not tocotrienols, lack this activity (Sundram, 1989). Gould et 
al. reported a statistically significant increase in tumor latency in the DMBA-
induced rat mammary tumor model with tocotrienols but not with tocopherols 
(Gould, 1995). Inhibition of tumor promotion by various palm-oil tocotrienols was also 
reported by Goh et al. (Goh, 1994), in an in vitro assay utilizing the activation of 
Epstein–Barr virus (EBV) early antigen expression in EBV-genome-carrying 
human lymphoblastoid cells. They showed that gamma- and delta-tocotrienol 
derived from palm oil exhibit strong activity against tumor promotion by inhibiting 
EBV early antigen expression in Raji cells induced by phorbol ester. However, 
alpha- and gamma-tocopherol and dimers of gamma-tocotrienol or gamma-
tocopherol lack this activity (Khanna, 2006). Iqbal et al. showed that feeding 
tocotrienol-rich fraction (TRF; 10 mg/kg) to DMBA-administered rats suppressed 
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mammary carcinogenesis, and this correlated with declines in serum cholesterol, 
low-density lipoprotein (LDL)-cholesterol, and HMG-CoA reductase protein (Parker, 
1993). Wada et al. examined the effect of 0.05% oral tocotrienols on spontaneous 
liver carcinogenesis in male mice and on glycerol-induced lung tumor promotion in 
male mice initiated with 4-nitroquinolone 1-oxide (Wada, 2005). Incidence of liver 
and lung tumors was almost 80% lower in treated animals than in untreated 
animals. Tocotrienols have been shown to prevent chemical-induced 
carcinogenesis of the liver (Iqbal, 2004) and found to suppress 2- 
acetylaminofluorene (AAF)-induced hepatocarcinogenesis (Ngah, 1991). In another 
study, Rahmat et al. (Rahmat, 1993) examined the effect of long-term administration 
of tocotrienols on hepatocarcinogenesis in rats. Liver carcinogenesis was induced 
by diethylnitrosamine and AAF in rats fed a diet containing 30mg/kg tocotrienols 
for 9 months. Expression ofbiomarkers of liver carcinogenesis suchas glutathione, 
alkaline phosphatase, and gamma-glutamyl transpeptidase was enhanced by the 
carcinogens but attenuated by tocotrienols, decreasing the impact of the 
carcinogens. A similar study by others confirmed these findings (Shamaan, 1993). All 
these studies suggest that tocotrienols have potential to both prevent and treat 
cancer. 
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2.4.1.2. VITAMIN E & MAST CELLS 
 
Dietary vitamin E supplementation is reported to alleviate the symptoms of 
inflammatory diseases (Meydani, 1995). The pathogenesis of atopic dermatitis (AD), 
an immunoglobulin (Ig)E-mediated hypersensitivity reaction, is characterized by 
the release of inflammatory mediators from mast cells. Effects of the preformed 
mast cell mediator histamine are mediated through histamine receptors (H1, H2). 
Stimulation of H1 on nerve cells causes pruritus. However, stimulation of H2 on 
neutrophils, lymphocytes, and monocytes inhibits the release of inflammatory 
mediators. The effect of histamine on blood vessels seems to be mediated via H1 
and H2, whereby it influences the vascular tone and permeability (Scott, 1995). It 
was hypothesized that in AD mast cells have an enhanced releasability for 
histamine (Hill, 2001). Proteases such as chymase and tryptase are also preformed 
mast cell mediators. In AD they are involved in the generation of bioactive 
peptides and they take part in the destruction of the extracellular matrix. The 
expression of mast cell proteases seems to be dependent on the 
microenvironment. Ricarelli and colleagues (Ricarelli, 1999) showed an inhibition of 
protease expression by vitamin E. Other mast cell mediators, such as 
prostaglandins, are produced and released immediately after stimulation. These 
de novo synthesized prostaglandins, especially prostaglandin D2 (PGD2), are 
known as pro-inflammatory mediators. PGD2 leads to peripheral vasodilatation, 
inhibits platelet aggregation and functions as a chemo-attractant for neutrophils. 
The rate-limiting enzyme in prostaglandin production (prostaglandin H synthase, 
PGHS) is regulated by reactive oxygen species (ROS) (Chappel, 1997). The 
production and release of these mast cell mediators therefore seems to be 
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dependent on membrane composition and redox state (Wolfreys, 1997). Vitamin E 
accumulates in biological membranes and stabilizes them. Furthermore, mast cells 
are able to generate ROS in response to different stimulants. It has been shown 
that ROS generation induced during mast cell activation is prevented by the 
antioxidant diphenyleneiodinium leading to reduced release of histamine (Matsui, 
2000). Gueck and colleagues demonstrate that vitamin E as a natural antioxidant 
also is involved in modulation of histamine release, prostaglandin D production 
and possibly chymase activity in the well-characterized canine mastocytoma cell 
line (C2). The author observed that the percentage of spontaneous and 
mastoparan (mast cell-degranulating peptide)-stimulated histamine release was 
reduced significantly in RRR-α-tocopherol-treated cells, otherwise chymase 
activity tended to be decreased by vitamin E but not tryptase (Gueck, 2002).  
The effects of tocopherols on the proliferation and signaling pathways in mast cells 
was evaluateded on the human mastocytoma cell line (HMC-1) by Kempna and 
colleagues (Kempna, 2004) . The tocopherols inhibited HMC-1 cell proliferation with 
different potency (δ>α = γ>β). Growth inhibition correlated with the reduction of 
PKB (protein kinase B) phosphorylation by the different tocopherols. The reduction 
of PKB phosphorylation led to a decrease of its activity, as judged from a parallel 
reduction of GSK phosphorylation. The tocopherols did not significantly change 
oxidative stress in HMC-1 cells, suggesting that the observed effects were not the 
result of a general reduction of oxidative stress. Thus, the tocopherols interfered 
with PKB phosphorylation and reduced the proliferation of HMC-1 cells, possibly 
by modulating either phosphatidylinositol 3-kinase, a kinase phosphorylating PKB 
(PDK1/2), or a phosphatase that dephosphorylates it. Inhibition of proliferation and 
PKB signalling in HMC-1 cells by vitamin E suggested a role in preventing 
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diseases with mast cell involvement, such as allergies, atherosclerosis, and 
tumorigenesis (Reiter, 2007). 
CHAPTER 3 IRON STATUS  
 
 
 
 
3 Iron profile 
 
 
3.1. Iron 
 
Iron is an essential element for many life forms, such as microbes, plants and 
higher animals. Its capacity to donate electrons and to receive plays a key role in 
many processes. This micronutrient is a cofactor of several systems redox 
enzyme, such as cytochromes; is involved in the transportation and storage of 
oxygen, because in the heme group of hemoglobin and myoglobin; takes part in 
DNA synthesis together with the enzyme ribonucleotidereduttase. However, the 
oxide-reducing capacity can result in the formation of radicals free that can 
damage cellular structures through the reactions of Fenton and Haber- Weiss 
(Gomme and McCann, 2005) The reaction leads to the formation of superoxide with the 
chemical formula O2−. Superoxide is biologically quite toxic and is deployed by the 
immune system to kill invading microorganisms. In phagocytes, superoxide is 
produced in large quantities by the enzyme NADPH oxidase for use in oxygen-
dependent killing mechanisms of invading pathogens. Mutations in the gene 
coding for the NADPH oxidase cause an immunodeficiency syndrome called 
chronic granulomatous disease, characterized by extreme susceptibility to 
infection, especially catalase positive organisms. In turn, micro-organisms 
genetically engineered to lack superoxide dismutase (SOD), lose virulence. 
Superoxide is also deleteriously produced as a byproduct of mitochondrial 
respiration , as well as several other enzymes, for example xanthine oxidase 
(Muller, 2007). Because superoxide is toxic, nearly all organisms living in the 
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presence of oxygen contain isoforms of the superoxide scavenging enzyme, 
superoxide dismutase, or SOD. SOD is an extremely efficient enzyme; it catalyzes 
the neutralization of superoxide nearly as fast as the two can diffuse together 
spontaneously in solution. Other proteins, which can be both oxidized and reduced 
by superoxide, have weak SOD-like activity (e.g. hemoglobin). Genetic inactivation 
("knockout") of SOD produces deleterious phenotypes in organisms ranging from 
bacteria to mice and have provided important clues as to the mechanisms of 
toxicity of superoxide in vivo. The biological toxicity of superoxide is due to its 
ability to inactivate the group iron-sulfur enzymes (which are important in many 
metabolic processes), thereby releasing iron in the simple cell, according to the 
Fenton reaction and generate the radical hydroxyl which is highly reactive. In its 
form HO2, superoxide can also initiate lipid peroxidation of polyunsaturated fatty 
acids. It also reacts with carbonyl compounds and halogenated carbons to create 
toxic peroxyl radicals. Superoxide may also react with nitric oxide (NO) forming 
ONOO-. Due to this reason, superoxide is a cause of oxidative stress (Sawyer, 2001; 
Muller, 2007). 
In mammals, there is no specific system for iron excretion, since its elimination is 
through the small quantities contained in the sweat (practically non-existent in 
domestic carnivores) or through the normal turnover of epithelial coating. The 
provisions martial contained in the enterocytes or in the keratinocytes in  
desquamation are, in fact, lost with the normal replacement of these. The body 
iron levels are then set only during the absorption phase in the proximal small 
intestine. The evolutionary pressure has selected an excellent system control 
uptake of this element, which is guaranteed with a normal amount of iron. 
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Especially in human medicine, the martial metabolism has long been subject of 
much research, but in recent years has only been possible to include with 
sufficient detail both the process of intestinal absorption of iron and its homeostatic 
regulation (Frazer and Anderson, 2005). 
 
 
3.2. IRON HOMEOSTASIS  
 
Six compartments can be distinguished in the distribution of body iron (Furlanello, 
1999): 
 
? Hemoglobin is the largest compartment of iron (approximately 67%). 
 
 
? Ferritin and hemosiderin are the storage compartments (27%). Ferritin is a 
ubiquitous molecule, composed by thousands of iron atoms incorporated 
into a protein shell (apoferritin); Hemosiderin is the name given to the 
martial reserves arising from the catabolism of ferritin, which are contained 
in monocytes,-macrophages, bone marrow, spleen and liver’s Kupffer cells. 
 
? Myoglobin (3.5%), structurally similar to hemoglobin, is present in striated 
muscle fibers and heart muscle cells 
 
 
? The fleeting compartment is the iron in interstitial fluid and intracellular 
(approximately 2.2%); here can be attached to cell membranes or 
intracellular proteins, for a relatively short period, before being incorporated 
into the heme or in storage proteins. 
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? The tissue compartment of the iron is very low (0.2%) and includes many 
classes of enzymes, such as those of cytochrome  
 
? The compartment plasma is the smallest, equal to about 0.08%, but is the 
most dynamic, because it is subject to changes (at least ten times a day). Is 
represented by transferrin (Tf), a glycoprotein, synthesized by liver, capable 
of carrying one or two atoms of ferric iron (Fe3+). 
 
 
 
3.3. IRON METABOLISM 
 
 
The heme group consists of the complex Fe2 + -protoporphyrin IX and is 
associated with several classes of proteins, including those used for the 
transportation (eg hemoglobin) and storage (eg myoglobin) oxygen; it is also 
present in some enzymes which became part of prosthetic groups (eg tryptophan 
pirrolasi). The iron heme-conjugate is then contained in high concentrations in the 
diets of meat (Wells and Award, 1995). The heme non-conjugated iron is often called 
"iron ion" or "iron inorganic, although the latter is a misnomer because it is found, 
in the form of ferric and ferrous, bound to organic acids (eg citrate) or peptides 
(ferritin and albumin) (Frazer, 2005; Mackenzie, 2005).In dogs, the heme iron is 
absorbed directly into the market share of 30%, while the non-heme iron, most 
unfortunately, is poorly absorbed (less than 10%) (Furlanello, 1999). 
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                                          Mackenzie e Garrick, 2005, modificato 
 
 
Iron is quantitatively the most important metal of human metabolism. It is used for 
the transport of oxygen, as a vehicle of electrons and as a catalyst for biochemical 
reactions essential for growth and proliferation cell. Physiologically, iron is almost 
present as ferrous ion (Fe2+) or ferric (Fe3+). Due to these ions are highly reactive; 
iron is normally bound to transport proteins (transferrin), storage proteins (ferritin) 
or component of functional complex (iron-porphyrins, metallo-enzymes). The 
protein binding prevents the ionized iron intervenes in reactions that can damage 
cellular structures. Under physiological conditions, the amount of iron in the body 
is strictly controlled to avoid a progressive depletion of intracellular stores that can 
lead to iron deficiency anaemia and to accumulation of metal that exceeds the 
storage capacity of the organism. This event would produce toxic reactions in the 
cells which cause irreversible damage especially in the liver, pancreas and heart 
(iron overload) (Brittenham, 1994) 
The erythroid bone marrow, erythrocytes of circulating blood or extravascular 
spaces (eg. of  the spleen) together constitute a functional form called eritrone. 
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The eritrone includes most of the iron in the body and is the most important 
metabolic site. The main metabolic pathway consists of a unidirectional flow of iron 
from transferrin, the transport protein, towards the eritrone and from there to the 
monocyte-macrophage system and again to the  transferrin plasmatica (Finch, 1982) 
An efficient recycling of iron, from red blood cells destroyed by macrophages to 
those newly formed in the bone marrow, is a characteristic of human metabolism 
martial. Physiologically, therefore, only a small part of total body iron is gained or 
lost every day. 
The balance of iron is the result of the difference between the amount of iron 
absorbed and eliminated from the body. Since the human body is unable to 
actively eliminate iron, the balance of the metal is set, solely, by monitoring the 
absorption intestinal (Cook, 1987). The two major physiological factors that influence 
the absorption is the amount of iron in the deposits and the level of erythropoietic 
activity. If iron stores decrease, absorption increases (negative feedback). The 
absorption increases, also, with increased erythropoietic activity, both in 
physiological and pathological conditions, characterized by ineffective 
erythropoiesis. The main carrier of iron is intracorporeal transferrin produced by 
hepatocytes. The ferritin is storage of iron (up to 4500 iron atoms); 99% is 
intracellular, 1% free in serum. The other form of storage more stable is 
hemosiderin. 
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3.4. IRON AND CANCER 
 
 
While iron plays an important role in many cellular functions, excess of iron 
storage induces DNA damage by generating hydroxyl radicals and thus promotes 
carcinogenesis. However, it remains unclear whether body iron levels that are 
commonly observed in a general population are related to oxidative DNA damage. 
It was examined the association between serum ferritin concentrations and levels 
of urinary 8-hydroxydeoxyguanosine (8-OHdG), a biomarker of systemic oxidative 
DNA damage and repair, in 528 Japanese men and women aged 21–67 years. 
Men had much higher ferritin levels than in women, and the levels were 
significantly greater in women aged 50 years or older than in women aged less 
than 50 years. Urinary 8-OHdG concentrations were significantly and positively 
associated with serum ferritin levels in all the subgroups. The Spearman rank 
correlation coefficients were 0.47, 0.76, and 0.73 for men overall, women aged 
less than 50 years, and women aged 50 years or older, respectively. These 
associations were materially unchanged after adjustment for potential confounding 
variables. In men, a more pronounced association was observed in non smokers 
than in smokers. These results suggest body iron storage is a strong determinant 
of levels of systemic oxidative DNA damage in a healthy population (Hori, 2009). 
In experimental animals (Sawa, 1998), excess intake of heme iron induces the 
formation of radicals and the occurrence of colon cancer. In humans, high dietary 
intake of heme iron (Lee, 2005; Zhou, 2005) and blood measurements of iron (Hann, 
1989; Knekt, 1994; Selby, 1988; Stevens, 1994) have been shown to be associated with 
an increased risk of cancer. 
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 More recently, a randomized control trial found that phlebotomy, accompanied by 
a considerable reduction in serum ferritin levels, significantly decreased risk of 
cancer in men with a peripheral arterial disease (Zacharski, 2008). Such evidence 
suggests  that cancer risk may vary according to body iron status even at levels 
commonly observed among the general population who do not have iron metabolic 
disorders. However, epidemiologic evidence regarding iron and cancer is far from 
consistent (Cross, 2006; Kato, 1999) and the finding from the above-mentioned trial 
should be interpreted cautiously because cancer was not the primary outcome 
(Zacharski, 2007). Investigations linking body iron to biomarkers  of carcinogenesis 
may provide data to support or refute whether iron level currently admitted as 
normal influences cancer risk. 
Urinary 8-hydroxydeoxyguanosine (8-OHdG) is a reliable biomarker of systemic 
oxidative DNA damage (Valko, 2006). Further, epidemiologic studies have shown 
that urinary 8-OHdG concentrations can predict cancer risk (Loft, 2006; Cooke, 2007; 
Thanan, 2008). However, few studies have been performed to quantify 8-OHdG 
levels in association with body iron status. Nakano et al. reported a positive 
correlation between serum ferritin concentrations and urinary 8-OHdG levels in 
2507 healthy men and women (Nakano, 2003). However, they did not control for 
smoking or body mass index, factors known to be associated with 8-OHdG levels 
(Kasai, 2001; Mizoue, 2007). In a small study of 48 mild dyslipidemic men, Tuomainen 
et al. demonstrated a linear, positive relationship between serum ferritin and 
urinary 8-OHdG with adjustment for smoking, body mass index, and physical 
activity (Tuomainen, 2007). To further explore this issue, the present study examined 
the association between serum ferritin concentrations, a marker of body iron 
storage (Kohgo, 2008) and urinary 8-OHdG levels in healthy men and women while 
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adjusting for potential confounding factors. In conclusion, a strong positive 
association was found between urinary 8-OHdG levels and serum ferritin 
concentrations in Japanese workers.  
This finding suggests that body iron storage is an important determinant of 
oxidative DNA damage, and thus supports a significant role for iron in 
carcinogenesis in a general population.  
 
In people, hyperferritinemia, unrelated to iron stores, is recognized in several 
malignancies, including tumors of histiocytic origin (Yoda, 1980; Valberg, 1980; Esumi, 
1989; Ya-You, 1998; Tang, 1987; Morita, 1981).  
Hyperferritinemia has been documented in several malignancies of dogs, and 
particularly in istiocytic sarcoma (HS) and lymphoma (Newlands, 1994; Kazmierski, 
2001). Ferritin is an iron storage and acute phase protein made by hepatocytes and 
cells of hematopoietic origin (Yoda, 1980). HS is an aggressive malignancy of 
antigen-presenting dendritic cells or phagocytic macrophages (Affolter, 2002; Moore, 
2006) and a serum tumor marker specific for HS would be a valuable diagnostic 
aid. Friedrichs and collegues investigated the diagnostic utility of serum ferritin 
concentration as a tumor marker to differentiate dogs with HS from dogs with 
inflammatory disease, liver disease, IMHA (immune-mediated hemolitic anemia), 
and lymphoma. They found that hyperferritinemia is common in dogs with HS, 
otherwise the highest mean ferritin concentration was found in dogs with IMHA. 
The highest ferritin concentration in the HS category was observed in a dog with 
both marked hemolytic anemia and marked hepatic necrosis. Because dogs with 
hyperferritinemia could be found in all disease categories, ferritin concentration 
merely above the reference interval does not appear to be a useful discriminatory 
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test for HS, otherwise dogs with marked hyperferritinemia (≥7,200 ng/mL) were 
more likely to have HS or IMHA than any of the other diseases. 
 
 
 
3.5. CAUSES OF IRON DEFICIENCY IN CANCER PATIENTS 
 
Cellular iron metabolism is homologous among most cell types; cellular iron 
homeostasis is primarily mediated by transferrin (Tf), transferrin receptor-1 (TfR1), 
and ferritin (Pantopoulos, 2004; Rouault, 2006; Muckenthaler, 2008). Tf is an iron transport 
protein with two iron-binding sites and is mainly found in the bloodstream, from 
which it circulates and delivers iron throughout the body. TfR1 is a ubiquitous 
membrane protein forming a complex with Tf, which initiates membrane 
endocytosis and serves as a major cellular iron uptake pathway. Excess iron 
within cells is stored in ferritin. When cells are iron deficient, iron regulatory 
proteins (IRPs) bind to iron responsive elements (IRE) in the 3′ untranslated region 
(UTR) of TfR1 mRNA as well as 5′ UTR of ferritin  mRNA. The IRP binding to 3′-
UTR results in TfR1 upregulation and increased iron uptake, but its binding to 5′-
UTR of ferritin leads to its downregulation and decreased iron storage (Rouault, 
2006; Muckenthaler, 2008; Recalcati, 2010). Iron depletion in cells by iron chelator 
desferoxamine mesylate (DFO) has been shown to increase hypoxia inducible 
factor-1alpha (HIF-1a) (Dongiovanni 2008; Salnikow, 2004) HIF-1a is a critical 
transcription factor for the regulation of vascular endothelial growth factor (VEGF), 
a potent inducer of tumor angiogenesis and metastasis (Bertout, 2008). However, 
direct evidence of iron deficiency on VEGF is lacking and the effect of iron 
deficiency on tumor angiogenesis has not yet been studied. To provide proof of 
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the concept that iron deficiency plays a role in angiogenesis, used shRNA 
techniques to knockdown TfR1 levels in the triple negative breast cancer MDA-
MB-231 cells. Because TfR1 is the gatekeeper of iron uptake, knocking down TfR1 
is similar to closing the door for iron entry; it physically disables iron uptake and 
causes stable iron deficiency in cells, thus mimicking IDA. Their results showed 
that iron deficiency in cells increased the angiogenic potential of the cells. 
This study is distinct from previous studies on iron overloadand its contribution to 
cancer initiation and promotion via oxidative stress pathways (Huang, 2003). In this 
study Has been demonstrated an important role for cellular iron deficiency in HIF-
1a stabilization, VEGF formation, and angiogenesis, suggesting that systemic iron 
deficiency and anemia in young breast cancer patients may make them more 
susceptible to tumor recurrence. 
Serum iron concentration can be considered potentially cancerogenic due to an 
increased formation of ROS and subsequent DNA damage and/or inactivation of 
proapoptotic factors as p53; on the other hand iron deficiency can be considered a 
tumour promoter, due to an increased HIF-1 production and subsequent increased 
VEGF serum concentrations. 
 
The human or canine cancer patient may show many changes when compared to 
normal subjects.  
 
? To have altered carbohydrate protein, and lipid metabolism.  
? Deficiencies iron not only but also in zinc, chromium  
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Human cancer patients with these deficiencies exhibited well-recognized 
paraneoplastic syndromes such as decreased glucose tolerance, cachexia, and 
anaemia. These patients also failed to thrive during treatment of their neoplastic 
disease.  
Iron metabolism is altered in the presence of inflammation or neoplasia. Serum 
concentrations of iron and total iron-binding capacity were lower in dogs with 
lymphoma and osteosarcoma compared to normal dogs. Serum ferritin 
concentration was higher in dogs with lymphoma compared to normal dogs and 
those with osteosarcoma. Signals for iron sequestration, as well as which protein 
principally serves as the iron storage pool, may differ within tumor type. Iron stores 
may be adequate in lymphoma and osteosarcoma, but the availability of iron for 
hemoglobin synthesis may be decreased. Such an effect could contribute to 
anemia of chronic disease in patients with inflammatory or neoplastic conditions. If 
sequestration is a protective mechanism against free iron oxidative injury, iron 
supplementation may be contraindicated. Alternatively, iron supplementation may 
improve erythropoiesis in clinically anemic patients, especially if the body is unable 
to release and use stored iron (Kathy J. 2001). 
Zinc deficiency is a common finding in human cancer patients, especially in those 
with head and neck cancer. Cell-mediated immunity and natural killer (NK) cell 
activity are suboptimal in zinc-deficient patients. Zinc-deficient cancer patients 
experience increased treatment morbidity, treatment delays, and unplanned 
hospitalizations. Chromium deficiency is a causative factor in decreased glucose 
tolerance, a recognized paraneoplastic syndrome. It can lead to hyperinsulinemia 
and hyperlactatemia, both of which have been observed in human and animal 
cancer patients. Serum zinc concentrations were decreased in dogs with 
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lymphoma and osteosarcoma. The cause of decreased serum zinc concentration 
is unknown, but it may be due to inadequate dietary intake or absorption, or it may 
reflect redistribution to other tissues such as liver. Zinc is required for the activity of 
numerous metallo-enzymes, including those involved in wound healing and repair 
of cellular damage. Zinc also is important for regulation of immune activity, 
including optimizing the function of T-helper cells and NK cells. Zinc deficiency 
may adversely affect immune competence, predisposing affected individuals to 
development of cancer. Alternatively, zinc deficiency and its associated immune 
suppression may represent a paraneoplastic syndrome secondary to certain types 
of cancer. Serum zinc concentration in cancer patients may be an indicator of how 
well such patients will respond to treatment. Canine cancer patients may benefit 
from zinc supplementation during therapy, especially those with low serum 
concentrations or those suffering from immunosuppression. Dogs with lymphoma 
and osteosarcoma had lower serum chromium concentrations than normal dogs. 
Both human and animal cancer patients exhibit decreased glucose tolerance and 
decreased insulin sensitivity, resulting in hyperinsulinemia.  
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5. MATHERIAL AND METHODS 
 
5.1 PATIENTS ELIGIBILITY 
Canine patients with a histologically confirmed diagnosis of epithelial and 
mesenchimal tumours and histologically or cytologically confirmed diagnosis of 
cutaneous mast cell tumours were prospectively enrolled from 2008 to 2010. Post 
diagnosis staging work-up included a complete physical examination, haematology 
and serum biochemical profile, abdominal ultrasound and three standard view of 
the thorax were also performed. Staging work-up in patients with a confirmed 
diagnosis of mast cell tumour included also a fine needle biopsy of sentinel lymph 
node, liver and spleen. Two control groups of healthy and “non neoplastic disease” 
dogs were also designed. Client owned healthy dogs were judged to be normal if 
there were no health complaints reported by the owner and no abnormalities 
detected on physical examination. All tumour-bearing dogs and dogs with 
nonneoplastic diseases were client owned and referred to the Veterinary Teaching 
Hospital of Pisa University for evaluation of a variety of medical disorders. All the 
patients enrolled in the study had no previous medical treatment.  
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5.2 GROUPS DESIGN 
Cancer patients were divided in three main groups:  
• Mast cell tumours 
• Epithelial tumours 
• Mesenchimal tumours  
 
Within the mast cell tumours’ group, patients were divided in two sub-groups 
based on the clinical stage of the disease:  
• Clinical stage 1 & 3: in this group were considered patients in clinical stage 
1 and 3, when as stage 3 were classified multiple dermal lesions with no 
presence of metastatic disease. According to the World Health Organization 
clinical staging system for mast cell tumours (Owen, 1980).  
• Clinical stage 2 & 4: in this group were considered patients in clinical stage 
2 and 4 (metastatic disease), According to the World Health Organization 
clinical staging system for mast cell tumours (Owen, 1980).  
Within the mast cell tumours’ group, patients were divided in two sub-groups 
based survived and deceased:  
• Survived: dogs alive at least 365 days after the diagnosis 
• Deceased: dogs deceased due to causes tumour related  
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5.3 SAMPLES COLLECTION 
Samples in EDTA and a serum gel tube were collected from canine cancer and 
nonneoplastic patients (12 hours fasted) and processed for haematology and 
complete serum biochemical profile at the time of the diagnosis (T0); at T0 thorax 
radiographs and abdominal ultrasound were also performed in all cancer patients. 
At T0 two heparinised tube and two serum gel tube were also collected (from both 
cancer groups and control groups) and centrifuged within 1 hour after 
venipuncture at 3000 r.p.m for 5 minutes (refrigered centrifuge ALC PK 120R, ALC 
International S.r.l., Milano, Italy) and stored at -80°C. These extra tubes were used for 
VEGF, ROMs, BAP, VItamine E (α-tochopherol) and iron serum profile analyses. 
 
5.4 LABORATORY ANALYSES  
 
5.4.1. IRON PROFILE 
iron status profile was evaluated on 500 µl of serum at the Laboratorio d’Analisi 
Veterinarie San Marco” (laboratorio d’analisi veterinarie San Marco, Padova, Italy) through: 
• Iron serum concentration* expressed as µg/dL  
•  Unsaturated iron-binding capacity (UIBC) serum concentration* expressed 
as µp/dL 
•  Ferritin serum concentration* expressed as ng/mL 
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•  Serum derived iron parameters: Total iron-binding capacity [TIBC] 
expressed as µp/dL and saturation %  
*laboratory methods are not shown on laboratory’s request. 
 
5.4.2. VEGF 
VEGF serum concentration was evaluated using a monoclonal canine VEGF 
antibody commercial (sandwich enzyme immunoassay technique) kit (Quantikine 
canine VEGF immunoassay, R&D systems inc., Minneapolis, USA). Sample preparation 
consisted in the dilution of 150 µl of plasma with 150 µl of calibrator diluents 
RD6U. For reagents preparation 20 mL of Wash buffer concentrate were gently 
mixed into deionized or distilled water to prepare 500 mL of wash buffer. The 
substrate solution was prepared mixing the color reagents A and B together in 
equal volumes within 15 minutes of use and protected from light. The VEGF 
standard was reconstitute with 1.0 mL of calibrator diluent RD6U. Polypropylene 
tubes were disposed to produce a dilution series and 500 µl of calibrator diluent 
RD6U were added into each tube. The stock solution was used to produce a 
dilution series (below). Each tube was mixed thoroughly before the next 
transfer. The undiluted standard served as the high Standard (2500 pg/mL). 
Calibrator diluent RD6U serves as the zero standard (0 pg/mL). 
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Quantikine  
Vegf 
immuno 
assay 
100 µl of assay diluent RD1W and 100 µl of Standard were added to each plasma 
diluted sample and then covered with adhesive strip and incubate for 2 hours at 
room temperature. Each sample was aspirated and washed with 400 µl of wash 
buffer repeating the process twice for a total of three washes. 200 µl of canine 
VEGF Conjugate were added to each and sampled were covered with a new 
adhesive strip and Incubated for 2 hours at room temperature. Samles were 
washed again as described before and 200 µl of substrate solution were added to 
each sample and protected from light and incubated for 25 minutes at room 
temperature. After 50 µl of stop solution were added to each sample, optical 
density was determined within 30 minutes, using a microplate reader set to 450 
nm. The results were expressed as pg/l 
 
5.4.3. ROMS & BAP TEST 
All the samples were examined with d-ROMs and BAP tests assessed by 
spectrophotometric method (Slim, SEAC, Florence, Italy). In d-ROMs test (Diacron 
International, Grosseto, Italy), reactive oxygen metabolites (hydroperoxides 
primarily) of a biological sample, in presence of iron released from plasma proteins 
by an acidic buffer, are able to generate alkoxyl and peroxyl radicals, according to 
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the Fenton’s reaction. Such radicals, in turn, are able to oxidize an alkyl-
substituted aromatic amine (N,N-dietylparaphenylendiamine), thus producing a 
pink-coloured derivative which is photometrically quantified at 505 nm (Alberti, 
2000). The ROM’s concentration runs directly parallel with colour intensity and is 
expressed as Carratelli Units (1 CARR U=0.08 mg hydrogen peroxide/dl). In BAP 
test (Diacron International, Grosseto, Italy) the addition of plasma sample to a 
coloured solution (thiocyanate), obtained by mixing a ferric chloride solution with a 
thiocyanate derivative solution, causes a decolouration, which intensity is 
measured photometrically at 505 nm and is proportional to the ability of plasma to 
reduce ferric ions (Benzie 1996). The results were expressed as μmol/l or reduced 
ferric ions. 
ROMs analytic procedure: 
After the preparation of the Standard solution (lyophilized), R1 (chromogen) 
and R2  (buffer) were brought  to 37°C. Three solution were prepared: blank 
(R1  +  R2  +  H20),  sample  (sample  +  R1+R2)  and  the  calibrator  (R1+R2+ 
calibrator). Solution were mixed and  incubated at 37°C  for 1 minute. Then 
the solutions underwent photometric reading (505 nm) at 37° for 1 minute. 
Further readings were performed at 1, 2 and 3 minutes. For the absorbance 
values  obtained  for  the  sample  and  the  calibrator  the  absorbance  of  the 
blank reagent was subtracted. Results were expressed  in U CARR according 
with the following equation: U CARR =  Δabs/min x F.  Δabs/min are the mean 
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differences of absorbance values measured at minute 1, 2 and 3. F is a correction 
factor with a predetermined value. Caratelli unite is equal to 0,08 mg di H2O2/dl. 
 
BAP analytic procedure 
R1 (chromogen), R2 (solution of ferric chloride [FECl3]) and R3 calibrator were 
brought to 37°C. Three solution were prepared: blank (R1 + R2 + H20), sample 
(sample + R1+R2) and the calibrator (R1+R2+ calibrator). Solution were mixed 
and  incubated  at  37°C  for  5  minute.  Then  the  solutions  underwent 
photometric  reading  (505 nm) at 37°  for 1 minute. Test’s  results,  the  iron‐
reducing  antioxidant  power  of  plasma, were  expressed  in  μ  iron‐reducing 
antioxidant equivalents per liter of sample, according to the formula: 
 [Abs blank – Abs sample] 
[Abs blank – Abs calibrator] 
X [calibrator] 
 
[Abs] are the absorbance values of the solutions measured at 505 nm 
[calibrator] is the concentration of the calibrator expressed as μmol/l. 
 
 
5.4.4. VITAMIN E (α-TOCHOPHEROL) 
α-tochopherol was assessed through a HPLC system by using a Chromosystems-
Diagnostic Kit HPLC & LC/MS® (Munchen, Germany). 200 μl of serum were added 
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to 20 μl of internal standard and to 25 μl of precipitation reagent I. Samples were 
vortex for 30 seconds and added with 400 μl of precipitation reagent II. Then 
samples were vortex for 30 seconds and centrifuged at 10000 rpm for 10 minutes. 
50 μl of supernatant were submitted to HPLC analysis. The HPLC system 
consisted of a Series 200 Perkin Elmer gradient Pump (Norwalk, CT, USA) 
coupled to a Series 200 Perkin Elmer variable UV detector (Norwalk, CT, USA), 
which was set at 325 nm and 254 nm. HPLC was interfaced with a personal 
computer by using an interface SERIES 600 Perkin Elmer (Norwalk, CT, USA). 
Integration of pikes was performed through Turbochrome Navigator software 
(Perkin Elmer). A chromatographic column (CHROMOSYSTEMS®, Munchen, 
Germany) was used. Instruments showed a wave length of 325 nm, which was 
switched to 295 nm after 3.5 minutes. The flux was set at 1.5 ml/min and 
temperature of the column was 25°C. The results were expressed as μmol/l 
 
 
 
 
 
 
CHROMSYSTEMS–DIAGNOSTICS BY HPLC & LCMS/MS® , München, Germany 
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5.5 STATISTICAL ANALYSIS 
Data were tested for normality by the Anderson-Darling Normality test. Data not 
normally distributed were log 10 transformed before analysis, except for iron, 
ferritin, UIBC, TIBC, Saturation and VEGF. Hematology data, serum biochemistry 
data, BAP, ROMs and Vitamin E were evaluated with one way Anova and Tukey’s 
Pairwise comparisons when differences between mast cell tumor, epithelial tumor, 
mesenchimal tumor, healthy patients and nonneoplastic patients. To analyze the 
difference within groups () the two samples t-test was used. For iron, ferritin, UIBC, 
TIBC, Saturation and VEGF that were not normally distributed, non-parametric 
tests were used (Mann-Whitney Test and Kruskal-Wallis Test). Correlations were 
evaluated Pearson’s test. Data were expressed as means and standard 
deviations, except where differently defined. Analyses were performed using the 
statistical package Minitab 16.1.1 (Minitab Inc., State College, USA). 
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6. RESULTS 
6.1 GROUPS DESCRIPTION 
The study included 24 dogs in the mast cell tumor group (12 females, 5 neutered 
females and 7 males), 10 dogs in the mesenchimal tumor group (7 females and 3 
males), 12 dogs in the epithelial tumor group (7 females, 1 neutered female and 4 
males), 12 dogs in the non neoplastic disease control group (6 females and 4 
males) and 10 dogs in the healthy control group (7 females and 3 males). Mean 
age in the groups were 8.3±2.1, 9.6±1.3, 10.5±1.9, 6.8±2.2 and 7.3±3.3 years, 
respectively. 
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Mast cell tumors group 
Breed Sex Age Diagnosis Clinical Stage 
Labrador Female  10 MCT 2°b 
Boxer Female 7 MCT 3°a 
Boxer Female 8 MCT 1°a 
French Bulldog Male 5 MCT 1°a 
Labrador Male 10 MCT 1°a 
Labrador Female 9 MCT 3°b 
Labrador Female neutered 8 MCT 1°a 
Cross breed Male 10 MCT 3°a 
Dobermann Female neutered 10 MCT 1°a 
Cross breed Male 4 MCT 1°a 
Boxer Female neutered 7 MCT 4°b 
Labrador Female neutered 10 MCT 2°b 
German Shepherd Male 10 MCT 4°b 
Beagle Female 10 MCT 1°a 
Golden retriever Female neutered 4 MCT 3°a 
Dachshund Female 6 MCT 1°a 
Labrador Female 9,5 MCT 4°b 
Cross breed Male 8 MCT 4°b 
Boxer Female 9 MCT 1°a 
Cross breed Female 8 MCT 4°b 
Cross breed Female 7 MCT 1°a 
Labrador Female 8 MCT 1°b 
Boxer Female 11 MCT 1°a 
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Mesenchimal tumors group 
Breed Sex Age Diagnosis Clinical Stage 
Maremma Sheepdog Female 9 Mixosarcoma T4 N0 M0 
Cross breed Female 9 HSA T2 N0 M0 
Cross breed Female 11 HSA T2 N2 M1 
Cross breed Male 8 Condrosarcoma T2 N0 M0 
Cross breed Female 11 Lipoblastoma Unknown 
Cross breed Male 11 HSA T2 N0 M0 
Boxer Male 10 HSA T3 N2 M1 
German Shepherd Female 8 Liposarcoma T4 N0 M0 
Golden retriever Female 8 Mixosarcoma T4 N0 M0 
Cross breed Female 11 OSA T2 M0 G2b 
 
Epithelial tumors group 
Breed Sex Age Diagnosis Clinical Stage 
Beagle Male 10 TCC T2 N0 M0 
Dobermann Male 7,5 Melanoma (Skin) T1 N0 M0 
Cross breed Female neutered 11 Mammary CA T2 N0 M1 
Irish Setter Female 11.5 Melanoma (oral) Stage I 
Cross breed Female 12 Undifferentiated CA T2 N0 M0 
Cross breed Female 14 Anal sac CA T2 N3 M0 
Siberian Husky Female 12 SCC (oral) T4 N2 M0 
Cross breed Male 11 melanoma (oral) Stage II 
German Shepherd Female 9 SCC (oral) T4 N1 M0 
Boxer Female 9 Melanoma (skin) T3 N1 M0 
AMSTAF Female 8 TCC T2 N0 M0 
Cocker spaniel Male 11 Melanoma (oral) Stage IV 
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Non neoplastic diseases control group 
Breed Sex Age Diagnosis 
Cross breed Female 10 GI tract disease 
Cross breed Male 12 Neurologic 
Pincher Female 2 LT respiratory disease 
German Shepherd Male 2 myositis 
Golden retriever Female 6 pyometra 
Labrador Male 9 GI tract disease 
Cross breed Female 8 IRC 
Cross breed Male 9 IRC 
Cross breed Female 6 IRC 
Cross breed Female 9 IRC 
 
Healthy control group 
Breed Sex Age 
Cross breed Female 10 
Setter irlandese Male 8 
Pointer Female 7 
German Shepherd Male 8 
Breton Female 5 
labrador Female 3 
Cross breed Female 6 
Dobermann Male 8 
Cross breed Female 4 
German Shepherd Female 9 
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6.2 IRON SERUM STATUS, SERUM VEGF AND OXIDATIVE STRESS 
PATTERN BETWEEN GROUPS  
Iron serum concentration was significantly higher in mast cell tumors (Mast cell 
tumors group) compared to mesenchimal tumors (Mesenchimal tumors group) 
(146.5±45.6 µg/dL and 96.5±50.8 µg/dL, respectively), while ferritin was 
significantly lower in the healthy dogs compared to all other groups (Table 1). No 
statistical significant differences were observed in UIBC, TIBC and iron saturation 
% between groups.  
Vascular Endothelial Growth Factor (VEGF) was significantly lower in healthy 
dogs (Healthy control group) compared to mast cell tumor, epithelial tumor and 
non neoplastic disease (Non neoplastic diseases control group). Patients affected 
by non neoplastic diseases showed a significantly higher VEGF than the 
mesenchimal tumors dogs (Table 2). 
Reactive Oxygen Molecules (ROMs) were significantly higher in cancer patients 
groups (Mast cell, Mesenchimal and Epithelial groups) than both the control 
groups (Healthy and Non neoplastic diseases control groups). Healthy control 
patients showed significantly higher Biological Antioxidant Potential (BAP) and 
Vitamin E values compared to the Non neoplastic diseases group, and in the 
Healthy group BAP was also significantly higher than in the Epithelial and Mast 
cell tumor groups groups (Table 3). 
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Table 1 Mean, standard deviation and median values of iron, ferritin, UIBC, TIBC and 
saturation in the three oncologic patient groups (Mast cell, Mesenchimal and Epithelial 
groups) and in the two control patients groups (Non neoplastic diseases and Healthy 
control groups). 
 N° Iron Ferritin UIBC TIBC Saturation 
  µg/dL ng/mL µp/dL µp/dL % 
MCT 24      
mean  146.6 166.6 205.2 353.7 44.1 
St. Dev.  45.6 101.7 68.2 74.8 15.5 
median  145.5 
B 129.5 B 210.5 355.0 41.1 
Mesenchimal 10      
mean  96.5 192.4 217.1 316.7 31.0 
St. Dev.  50.8 89.1 77.0 93.4 15.1 
median  91.5 
A 189.0 B 243.0 323.0 28.7 
Epithelial 12      
mean  137.3 191.9 241.2 380.2 36.8 
St. Dev.  53.6 106.2 74.6 80.9 12.5 
median  114.5 210.5 
B 259.0 384.0 33.5 
Non neopl. dis. CTR 10      
mean  115.8 152.4 231.1 345.9 35.9 
St. Dev.  26.2 60.2 63.9 75.0 8.8 
median  102.5 146.5 
B 251.0 372.0 34.5 
Healthy CTR 10      
mean  120.9 89.0 230.8 358.6 33.5 
St. Dev.  19.2 18.1 28.0 28.5 4.9 
median  121.0 85.5 
A 239.5 351.5 33.1 
Kruskal-Wallis Test  P = 0.023 P = 0.020 n.s. n.s. n.s. 
Mann-Whitney Test: A≠B, C≠D (P<0.05) 
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Table 2 Mean, standard dediation and median values of VEGF in the three oncologic 
patients groups (Mast cell, Mesenchimal and Epithelial groups) and in the two control 
patient groups (Non neoplastic diseases and Healthy control groups). 
 n VEGF 
  pg/mL 
MCT 24  
mean  99.6 
St. Dev.  26.8 
median  85.6B 
Mesenchimal 10  
mean  91.3 
St. Dev.  48.4 
median  79.5 C 
Epithelial 12  
mean  137.6 
St. Dev.  135.4 
median  99.3 B 
Non neopl. dis. CTR 10  
mean  199.4 
St. Dev.  165.8 
median  129.8 B,D 
Healthy CTR 10  
mean  76.3 
St. Dev.  23.4 
median  73.1 A 
Kruskal-Wallis Test  P = 0.012 
Mann-Whitney Test: A≠B; C≠D (P<0.05) 
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Table 3 Mean, standard deviation and median values of ROMs, BAP and Vitamin E in 
the three oncologic patients groups (Mast cell, Mesenchimal and Epithelial groups) and in 
the two control patient groups (Non neoplastic diseases and Healthy control groups). 
 N° ROMs BAP  Vitamin E 
MCT 23 U Carr mmol/L µmol/L 
mean  136.7 B 2026.0 B 26.1 A 
St. Dev.  33.0 220.7 11.8 
median  139.8 1953.0 25.6 
Mesenchimal 10    
mean  154.4 B 2217.1 17.0 
St. Dev.  23.3 243.7 5.6 
median  149.6 2238.5 15.4 
Epithelial 12    
mean  155.4 B 2202.0 B 22.9 
St. Dev.  25.8 240.2 9.9 
median  150.9 2189.5 24.2 
Non neopl. dis. CTR 10    
mean  96.3 A 2156.3 B 11.7 B 
St. Dev.  41.7 875.5 12.7 
median  91.5 1949.0 6.3 
Healthy CTR 10    
mean  71.9 A 2762.1 A 26.3 A 
St. Dev.  11.3 643.9 5.3 
median  71 2553.5 23.8 
One way ANOVA 
 
 P=0.000 P=0.003 P=0.001 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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6.3 DIFFERENCES IN IRON SERUM STATUS, SERUM VEGF AND 
OXIDATIVE STRESS PATTERN WITHIN MCT PATIENT GROUPS 
Iron serum status (Table 4), VEGF serum concentration (Table 5), ROMs, BAP 
and Vitamin E (Table6) showed no statistically significant differences between the 
two MCT sub-groups based on the clinical stage of the disease (Clinical stage 1 & 
3, Clinical stage 2 & 4) 
 
Table 4 Mean, standard deviation and median values of iron, ferritin, UIBC, TIBC and 
saturation in Clinical stage 1 & 3 MCT and Clinical stage 2 & 4 MCT 
 N° Iron Ferritin UIBC TIBC Saturation  
Clinical stage 1 & 3 17 µg/dL ng/mL µp/dL µp/dL % 
mean  138.4 145.2 214.6 353.2 42.3 
St. Dev.  21.8 83.6 65.4 69.1 11.8 
median  143.0 127.0 210.0 370.0 40.5 
Clinical stage 2 & 4 7      
mean  166.3 218.4 182.4 354.9 48.7 
St. Dev.  77.9 128.8 74.6 93.3 22.8 
median  148.0 224.0 211.0 328.0 41.4 
Mann-Whitney test  n.s n.s n.s n.s n.s 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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Table 5 Mean, standard deviation and median values of VEGF in Clinical stage 1 & 3 
MCT and Clinical stage 2 & 4 MCT 
 N° VEGF 
Clinical stage 1 & 3 17 pg/mL 
mean  98.3 
St. Dev.  28.5 
median  84.5 
Clinical stage 2 & 4 7  
mean  103.0 
St. Dev.  23.8 
median  85.9 
Mann-Whitney test  n.s 
 
Table 6 Mean, standard deviation and median values of ROMs, BAP and Vitamin E in 
Clinical stage 1 & 3 MCT and Clinical stage 2 & 4 MCT 
 N° ROMs BAP Vitamin E 
Clinical stage 1 & 3 16 U Carr mmol/L µmol/L 
mean  138.6 2001.9 25.9 
St. Dev.  30.7 163.5 12.9 
median  147.5 1952.0 23.6 
Clinical stage 2 & 4 7    
mean  132.5 2081.0 29.5 
St. Dev.  40.1 326.7 9.3 
median  119.4 2104.0 32.6 
Two samples t-test  n.s. n.s. n.s. 
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Iron serum status (Table 7), VEGF serum concentration (Table 8), ROMs, BAP 
and Vitamin E (Table 9) showed no statistically significant differences between the 
two MCT sub-groups based on survived and deceased patients (survived and 
deceased) 
 
Table 7 Mean, standard deviation and median values of iron, ferritin, UIBC, TIBC and 
saturation in Deceased MCT and Survived MCT. 
 N° Iron Ferritn UIBC TIBC Saturation
Deceased 5 µg/dL ng/mL µp/dL µp/dL % 
mean  164.8 277.0 170.4 335.2 49.1 
St. Dev.  94.0 99.3 87.9 92.2 27.6 
median  138 254 200 320 40.8 
Survived 18      
mean  141.4 140.8 214.6 360.2 42.9 
St. Dev.  24.7 83.2 63.4 73.4 11.8 
median  146.2 124.5 211.5 370 41.4 
Mann-Whitney test  N.S. P=0.0101 N.S. N.S. N.S. 
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Table 8 Mean, standard deviation and median values of VEGF serum concentration in 
Deceased MCT and Survived MCT 
 N° VEGF 
Deceased 5 pg/mL 
mean  103.3 
St. Dev.  26.9 
median  85.6 
Survived 18  
mean  97.6 
St. Dev.  27.8 
median  85.0 
Mann-Whitney test  N.S. 
 
Table 9 Mean, standard deviation and median values of VEGF serum concentration in 
Deceased MCT and Survived MCT 
 N° ROMs BAP  Vitamin E 
Deceased 5 U Carr mmol/L µmol/L 
mean  145.5 2040 25.4 
St. Dev.  40.8 386.7 7.3 
median  134.8 1949 25.6 
Survived 17    
mean  136.5 2007.9 26.5 
St. Dev.  31.0 160.2 12.7 
median  146.4 1953 23.7 
Mann-Whitney test  N.S. N.S. N.S. 
 
CHAPTER 6 RESULTS 
 
 
 
 
83 
 
6.4 DIFFERENCES IN HAEMATOLOGICAL PROFILE BETWEEN GROUPS 
AND WITHIN MCT SUB GROUPS  
Hematology: total white blood cells (WBC) were significantly higher in 
mesenchimal tumor (Mesenchimal tumors group) compared to mast cell tumors 
(Mast cell tumors group) (17.6±15.3 109/L and 8.8±3.6 109/L, respectively). 
Platelets count (PLT) was significantly higher in epithelial tumors than in mast cell 
tumor (Table 10). No statistical significant differences were observed for the other 
parameters between groups. Within the MCT sub groups total WBC were higher in  
Deceased patients than in Survived (Table 12). Red blood cells (RBC) were lower 
in Clinical stage 2 & 4 MCT than Clinical stage 1 & 3 MCT and PLT vice versa 
(Table 11). No statistical significant differences were observed for the other 
parameters.  
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Table 10 Mean and standard deviation of haematological parameters between groups. 
 
 WBC 
 
(6-17) 
109/L 
RBC 
 
(5.5-7.9) 
109/L 
Hgb 
 
(12-
18.5) 
1012/L 
Hct 
 
37-55 
% 
MCV 
 
60-76 
fL 
MCH 
 
20-27 
pg 
MCHC 
 
32-38.5 
g/dL 
RDW 
 
12-16 
% 
PLT 
 
150-400 
109/L 
MPV 
 
7.9-12 
fL 
Pct 
 
0.15-0.30 
% 
Epithelial(n=12)            
Mean 10.0 AB 6.3 14.3 42.2 66.9 22.6 33.8 12.5 352.9A 10.6 0.38° 
St. dev. 2.3 1.1 2.8 7.7 3.3 1.5 1.3 1.1 128.8 0.8 0.11 
            
MCT (n=24)            
Mean 8.8 B 6.3 14.6 43.3 68.0 23.0 33.7 12.6 257.7B 11.0 0.28B 
St. dev. 3.6 0.9 2.2 6.3 3.5 1.6 1.1 0.7 65.8 0.8 0.07 
            
Mesenchimal 
(n=10) 
           
Mean 17.6 A 6.0 14.0 41.2 68.5 23.3 34.0 13.6 279.0AB 11.1 0.31AB 
St. dev. 15.3 1.4 3.5 9.9 3.5 1.4 1.9 2.8 93.1 1.1 0.10 
            
One way 
ANOVA 
 
P=0,009 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
P=0.019 
 
n.s. 
 
P=0.016 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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Table 11 Mean and standard deviation of haematological parameters in Deceased MCT and Survived MCT 
 WBC 
 
(6-17) 
109/L 
RBC 
 
(5.5-7.9) 
109/L 
Hgb 
 
(12-18.5) 
1012/L 
Hct 
 
37-55 
% 
MCV 
 
60-76 
fL 
MCH 
 
20-27 
pg 
MCHC 
 
32-38.5 
g/dL 
RDW 
 
12-16 
% 
PLT 
 
150-400 
109/L 
MPV 
 
7.9-12 
fL 
Pct 
 
0.15-0.30 
% 
Deceased 
(n=5) 
           
Mean 13.3 5.7 13.4 39.7 69.2 23.3 33.6 12.6 207.0 11.5 0.24 
St. dev. 5.3 0.8 2.3 6.5 4.7 1.7 1.4 0.7 65.6 1.2 0.07 
            
Survived 
(n=18) 
           
Mean 7.6 6.5 15.0 44.4 67.8 23.0 33.8 12.6 271.7 10.9 0.30 
St. dev. 1.8 0.9 2.1 6.3 3.2 1.6 1.1 0.7 62.3 0.7 0.06 
            
2 sample 
t-test 
 
P=0,026 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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Table 12 Mean and standard deviation of haematological parameters in Clinical stage 1 & 3 MCT and Clinical stage 2 & 4 MCT 
 
 WBC 
 
(6-17) 
109/L 
RBC 
 
(5.5-7.9) 
109/L 
Hgb 
 
(12-18.5) 
1012/L 
Hct 
 
37-55 
% 
MCV 
 
60-76 
fL 
MCH 
 
20-27 
pg 
MCHC 
 
32-38.5 
g/dL 
RDW 
 
12-16 
% 
PLT 
 
150-400 
109/L 
MPV 
 
7.9-12 
fL 
Pct 
 
0.15-0.30 
% 
STAGE 1+3  
(n=17) 
           
Mean 7.70 6.57 15.15 44.74 67.65 22.92 33.82 12.53 275.3 10.93 0.30 
St. dev. 1.82 0.94 2.15 6.30 3.28 1.64 1.12 0.64 62.3 0.68 0.06 
            
STAGE 2+4  
(n=7) 
           
Mean 11.50 5.76 13.44 39.74 6.86 23.14 33.54 12.79 215.0 11.41 0.24 
St. dev. 5.30 0.70 1.92 5.35 4.02 1.50 1.16 0.87 57.0 1.1 0.06 
            
2 sample t-test  
n.s. 
 
P=0,033 
 
n.s. 
(P=0.081)
 
n.s. 
(P=0.070)
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
P=0.041 
 
n.s. 
 
n.s. 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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6.5 DIFFERENCES IN BIOCHEMICAL PROFILE BETWEEN GROUPS AND 
WITHIN MCT SUB GROUPS  
No significant differences were observed within the biochemical profile between 
groups except for total protein that were significantly higher in MCT and 
mesenchimal tumor than in mesenchimal ones (Table 13). No statistical 
differences were observed when Deceased MCT group was compared with Survived 
MCT except for prothrombin time (PT) that was significantly lower in deceased patients 
than in survived (Table 13). When Clinical stage 1 & 3 MCT and Clinical stage 2 & 4 MCT 
were compared, total bilirubin was significantly higher in patients with stage 2&4 than 1&3 
and PT was significantly higher in stage 1&3 than in stage 2&4 (Table 15). 
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Table 13 Mean and standard deviation of biochemical parameters between groups. 
 
 
Total Ca 
Mg/dL (8-
11) 
Phosphorus 
Mg/dl (2.9-5) 
Total protein 
g/dl (5.5-7.7) 
Albumin 
g/dL(2.5-4)
ALKP 
U/L (77-
200) 
GGT 
U/L (2.9-12.6) 
ALT 
U/L (31-95) 
Urea 
Mg/dL (20-
60) 
Creatinin 
Mg/dL(0.8-1.5) 
Total bilirubin 
Mg/dL0.13-
0.3 
Epithelial 
N=12 
          
Mean 9.03 3.95 5.62 B 2.81 251.3 11.29 70.84 34.17 1.11 0.35 
St. dev. 0.79 1.25 0.97 0.45 186.4 7.02 29.13 20.96 0.55 0.33 
           
MCT  
N=24 
          
Mean 9.25 4.15 6.81 A 2.92 225.8 12.35 64.15 28.31 0.97 0.38 
St. dev. 1.04 1.09 0.76 0.47 387.1 6.83 33.96 7.86 0.15 0.34 
           
Mesenchimal 
N=10 
          
Mean 8.92 4.06 6.70 A 2.74 403.0 13.53 92.50 36.07 0.97 0.23 
St. dev. 1.02 0.67 0.78 0.58 480.0 6.88 63.80 15.74 0.18 0.08 
           
One way  
ANOVA 
n.s. 
 
n.s. 
 
P=0,001 n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
 
n.s. 
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 Cholesterol 
Mg/dL (150-265) 
Triglycerides 
Mg/dL (66-110) 
Glucose 
Mg/dL (80-120) 
PT 
Sec (5.2-7.6) 
APTT 
Sec (9-20) 
Epithelial N=12      
Mean 220.3 95.23 91.39 6.77 13.02 
St. dev. 62.0 100.76 9.38 0.83 1.98 
      
MCT  
N=24 
     
Mean 244.6 79.76 97.20 6.83 13.52 
St. dev. 89.7 46.23 13.27 0.88 2.43 
      
Mesenchimal 
N=10  
     
Mean 195.4 59.19 89.79 7.52 13.80 
St. dev. 108.3 23.98 15.88 0.97 2.91 
      
One way 
ANOVA 
n.s. 
 
n.s. 
 
n.s 
 
n.s. 
 
n.s. 
 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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Table 14 Mean and standard deviation of biochemical parameters in Deceased MCT and Survived MCT  
 Total Ca 
Mg/dL (8-11) 
Phosphorus 
Mg/dl (2.9-5) 
Total protein 
g/dl (5.5-7.7) 
Albumin 
g/dL(2.5-4) 
ALKP 
U/L (77-
200) 
GGT 
U/L (2.9-12.6) 
ALT 
U/L (31-95) 
Urea 
Mg/dL (20-60) 
Creatinin 
Mg/dL(0.8-1.5) 
Total bilirubin 
Mg/dL0.13-0.3 
Deceased 
N=5 
          
Mean 8.94 4.24 6.86 3.01 234.22 10.08 68.24 28.38 0.89 0.73 
St. dev. 0.53 1.14 0.79 0.60 152.54 4.30 14.87 4.00 0.21 0.67 
           
Survived 
N=18 
          
Mean 9.40 4.17 6.82 2.93 215.44 12.92 61.75 28.20 1.00 0.28 
St. dev. 1.13 1.12 0.80 0.44 442.64 7.54 38.30 8.93 0.14 0.08 
           
2 sample 
t-test 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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 Cholesterol 
Mg/dL (150-265) 
Triglycerides 
Mg/dL (66-110) 
Glucose 
Mg/dL (80-120) 
PT 
Sec (5.2-7.6) 
APTT 
Sec (9-20) 
Deceased 
N=5 
     
Mean 249.70 85.82 104.68 6.20 13.14 
St. dev. 91.08 58.26 16.45 0.48 1.39 
      
Survived 
N=18 
     
Mean 238.16 76.39 95.68 7.02 13.58 
St. dev. 91.66 44.90 12.24 0.91 2.73 
2 sample 
t-test 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
P=0.020 
 
 
n.s. 
 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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Table 15 Mean and standard deviation of biochemical parameters in Clinical stage 1 & 3 MCT and Clinical stage 2 & 4 MCT 
 Total Ca 
Mg/dL (8-11) 
Phosphorus 
Mg/dl (2.9-5) 
Total protein 
g/dl (5.5-7.7) 
Albumin 
g/dL(2.5-4) 
ALKP 
U/L (77-200)
GGT 
U/L (2.9-12.6) 
ALT 
U/L (31-95)
Urea 
Mg/dL (20-60)
Creatinin 
Mg/dL(0.8-1.5)
Total bilirubin 
Mg/dL0.13-0.3 
ST 1+3 
N=17 
          
Mean 9.45 4.15 6.83 2.87 222.7 12.51 61.11 27.79 0.99 0.266 
St. dev. 1.14 1.15 0.81 0.39 455.2 7.56 39.38 9.03 0.14 0.071 
           
ST 2+4 
N=7 
          
Mean 8.77 4.15 6.74 3.04 233.3 11.94 71.56 29.57 0.94 0.646 
St. dev. 0.54 1.01 0.68 0.65 148.1 5.11 14.02 4.12 0.19 0.568 
           
2 
sample 
t-test 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
P=0,031 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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 Cholesterol 
Mg/dL (150-265) 
Triglycerides 
Mg/dL (66-110) 
Glucose 
Mg/dL (80-120) 
PT 
Sec (5.2-7.6) 
APTT 
Sec (9-20) 
ST 1+3 
N=17 
     
Mean 234.5 76.65 97.21 7.02 13.77 
St. dev. 93.1 46.27 10.71 0.94 2.69 
      
ST 2+4 
N=7 
     
Mean 269.0 87.30 97.17 6.37 12.90 
St. dev. 81.9 48.88 19.22 0.51 1.63 
      
2 
sample 
t-test 
 
n.s. 
 
 
n.s. 
 
 
n.s. 
 
 
P=0.040 
 
 
n.s. 
 
Tukey’s pairwise comparisons: A≠B (P<0.05) 
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6.6 PROPORTION OF CANCER PATIENTS OUTSIDE THE REFERENCE 
RANGE (IRON PROFILE, VEGF, OXIDATIVE STRESS PATTERN)  
In cancer groups the 50% of the patients affected by mesenchimal tumors showed 
hyposideremia while this occurred in 16.7% of epithelial tumor and just 8.3% of 
MCT; hyposideremia occurred also in 10% of the healthy patients. Hypersideremia 
was rare, happening in 8.3% of MCT and 8.3% of epithelial tumor. Ferritin was low 
in 50% of the healthy patients as well in 20% of the Non neoplastic diseases group 
and within the cancer groups MCT showed the highest variability with 25% of the 
patients under the reference range and 12.5% above the reference range. ROMs 
values of the three oncologic groups were always higher than the normal 
reference interval derived from (Pasquini et al 2008). BAP was always in the 
reference range in all the cancer groups as well as in the other groups. The 
reference range for vitamine E was calculated based on the healthy control group 
(19.9-35.9 µmol/L) and was found to be under the reference range in 80% of the 
mesenchimal tumor as well as the 80% of the Non neoplastic diseases group. 
MCTs and epithelial tumors showed a Vitamin E under the reference range in the 
39.1 and 33.3% respectively. Within the cancer groups vitamin E was found to be 
increased in the 17.4 % of the MCTs and 8.3% of the epithelial tumor. VEGF of the 
cancer groups and Non neoplastic disease was compared with the healthy 
patients and was found to be increased in 30% of MCT, 20% of the mesenchimal 
tumor and 16.7% of the epithelial tumour. 60% of the Non neoplastic disease 
group patients had elevation in VEGF serum concentration (Table 16).  
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 Table 16 Proportion of cancer patients below and above the reference range (iron profile, 
VEGF, Oxidative stress pattern)  
 Iron µg/dL Ferritin ng/mL UIBC µp/dL TIBC µp/dL Saturation % 
Out of 
range 
<95 >226 <85 >286 <182 >306 <318 >479 <28.2 >56.8 
MCT 2/24 
(8.3%) 
2/24 
(8.3%) 
6/24 
(25%) 
3/24 
(12.5%)
5/24 
(20.8%)
2/24 
(8.3%)
5/24 
(20.8%) 
2/24 
(8.3%) 
2/24 
(8.3%) 
4/24 
(16.7%)
MESEN 5/10 
(50.0%)
0/10 
(0%) 
1/10 
(10%) 
0/10 
(0%) 
4/10 
(40%) 
0/10 
(0%) 
5/10 
(50%) 
0/10 
(0%) 
5/10 
(50%) 
0/10 
(0%) 
EPIT 2/12 
(16.7%)
1/12 
(8.3%) 
2/12 
(16.7%)
1/12 
(8.3%) 
3/12 
(22.2%)
1/12 
(8.3%)
2/12 
(16.7%) 
1/12 
(8.3%) 
2/12 
(16.7%)
0/12 
(0%) 
CTR H 1/10 
(10%) 
0/10 
(0%) 
5/10 
(50%) 
0/10 
(0%) 
0/10 
(0%) 
0/10 
(0%) 
1/10 
(10%) 
0/10 
(0%) 
1/10 
(10%) 
0/10 
(0%) 
CTR 
PAT 
0/10 
(0%) 
0/10 
(0%) 
2/10 
(20%) 
0/10 
(0%) 
3/10 
(30%) 
0/10 
(0%) 
3/10 
(30%) 
0/10 
(0%) 
1/10 
(10%) 
0/10 
(0%) 
 
 ROMs U-Carr BAP mmol/L Vit. E µmol/L VEGF pg/mL 
Out of 
range 
<56.3* >91.1* <1305* >3587* <19.9§ >35.9§ <46.6§ >117.5§ 
MCT 0/23 
(0%) 
23/23 
(100%) 
0/23 
(0%) 
0/23 
(0%) 
9/23 
(39.1%)
4/23 
(17.4%)
0/23 
(0%) 
7/23 
(30.4%) 
MESEN 0/10 
(0%) 
10/10 
(100%) 
0/10 
(0%) 
0/10 
(0%) 
8/10 
(80%) 
0/10 
(0%) 
1/10 
(10%) 
2/10 
(20%) 
EPIT 0/12 
(0%) 
12/12 
(100%) 
0/12 
(0%) 
0/12 
(0%) 
4/12 
(33.3%)
1/12 
(8.3%) 
0/12 
(0%) 
2/12 
(16.7%) 
CTR H 1/10 
(10%) 
0/10 
(0%) 
0/10 
(0%) 
2/10 
(20%) 
0/10 
(0%) 
0/10 
(0%) 
0/10 
(10%) 
0/10 
(0%) 
CTR 
PAT 
1/10 
(10%) 
5/10 
(50%) 
1/10 
(10%) 
1/10 
(10%) 
8/10 
(80%) 
0/10 
(0%) 
0/10 
(0%) 
6/10 
(60%) 
*Reference interval was obtained from Pasquini et al 2008 (mean±1.96standard 
deviation) 
 §Lower and higher values of the Healthy control group 
 
Within the MCT Clinical stage 1 & 3 MCT and Clinical stage 2 & 4 MCT groups, 
hypersideremia and hyposideremia occurred just in Clinical stage 2 & 4 MCT group. 
Ferritin was low in the 27.8% of the Clinical stage 1 & 3 MCT. As reported before 100% of 
the of the MCT showed increase of ROMs and normal BAP. Vitamin E was reduced in 
41% of the Clinical stage 1 & 3 compared with the 28.6% of the Clinical stage 2 & 4. 
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VEGF was found to be higher in 42.8% of the stage Clinical stage 2 & 4 compared with 
the 22.2% of the Clinical stage 1 & 3. 
Table 17 Proportion of Clinical stage 1 & 3 MCT and Clinical stage 2 & 4 MCT below and 
above the reference range (iron profile, VEGF, Oxidative stress pattern) 
 Iron µg/dL Ferritin ng/mL UIBC µp/dL TIBC µp/dL Saturation % 
Out of 
range 
<95 >226 <85 >286 <182 >306 <318 >479 <28.2 >56.8 
Stage 
1+3 
0/18 
(0%) 
0/18 
(0%) 
5/18 
(27.8%) 
2/18 
(11.1%)
4/18 
(22.2%)
2/18 
(11.1%)
4/18 
(22.2%) 
2/24 
(8.3%) 
1/18 
(5.5%) 
3/18 
(16.7%)
Stage 
2+4 
2/7 
(28.6%) 
2/7 
(28.6%) 
1/7 
(14.3%) 
1/7 
(14.3%)
1/7 
(14.3%)
0/7 
(0%) 
2/7 
(28.6%) 
2/7 
(28.6%) 
1/7 
(14.3%)
1/7 
(14.3%)
 
 ROMs U-Carr BAP mmol/L Vit. E µmol/L VEGF pg/mL 
Out of 
range 
<56.3* >91.1* <1305* >3587* <19.9§ >35.9§ <46.6§ >117.5§ 
Stage 
1+3 
0/17 
(0%) 
17/17 
(100%) 
0/17 
(0%) 
0/17 
(0%) 
7/17 
(41.2%)
3/17 
(17.6%)
0/18 
(0%) 
4/18 
(22.2%) 
Stage 
2+4 
0/7 
(0%) 
7/7 
(100%) 
0/7 
(0%) 
0/7 
(0%) 
2/7 
(28.6%)
1/7 
(14.3%)
0/7 
(10%) 
3/7 
(42.8%) 
*Reference interval was obtained from Pasquini et al 2008 (mean±1.96standard 
deviation) 
 §Lower and higher values of the CTR H group 
 
Mortality within 1 year from diagnosis of MCT was higher among dogs belonging 
to Stages 2+4 compared to those belonging to Stages 1+3: 5/7 (71.4%) and 0/17 
(0%), respectively (Fisher’s exact test: P<0.001). 
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6.7 RELATIONS BETWEEN VARIABLES 
Scatter plot graphs and Pearson’s correlations of the variables between all the oncologic 
groups were performed and the statistically significant are reported below. 
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Scatter plot graphs and Pearson’s correlations of the variables within MCT sub groups 
were performed and the statistically significant are reported below. 
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7. DISCUSSION 
 
Aim of this prospective study was to evaluate Iron status, VEGF serum 
concentration, and oxidative stress pattern thorough ROMs, BAP and Vitamin E 
serum concentration in canine cancer patients focusing on canine mast cell 
tumours.  
ROMs, BAP and Vitamine E have been evaluated in vivo in groups of non 
Hodgkin’s lymphoma canine patients (Vajdovich, 2005; Winter, 2009); in these studies a 
significant increase of ROMs and reduction of BAP was observed. In our study we 
enrolled epithelial, mesenchimal and round cell tumours (MCT) observing and 
increase of ROMs in all the cancer patients when compared with the reference 
range and our population of healthy dogs. Although none of the oncologic patients 
showed BAPs values below the reference range (Pasquini, 2008), the values of 
the healthy dogs were significantly higher than those affected by MCT, epithelial 
tumours and non neoplastic disease. Patients with mesenchimal tumours despite 
a significant increase of ROMs had no significant differences in BAP when 
compared with healthy dogs. This could be related with the heterogeneous and 
small population of tumour enrolled, and significance maybe reach increasing the 
number of patients. It is thus possible that the range for healthy animals derived 
from the study of Pasquini (2008) was particularly wide, despite the fact that it was 
obtained from dogs belonging to one single breed (Labrador retriever). Although it 
is expected that an increase of ROMs would be related with a decrease of BAP, 
this was observed only in MCT tumours group. This result could be due to the 
small number of epithelial and mesenchimal tumours; moreover have to be 
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considered that MCTs group was composed by an homogeneous population of 
cancer, different from the other two groups (epithelial and mesenchimal tumors) 
where different biological entity were considered together. In our study, Vitamin E 
was not significantly decreased in cancer patients when compared to the healthy 
group, although mesenchimal tumours approached significance. Is interesting how 
Vitamin E was negatively correlated with ROMs when all the cancer patients were 
considered together; this maybe explained with the fact that not all the substances 
taking part in the BAP (i.e. Vitamin C, GSH, γ-Tocopherol, ORAC, metallothionein), 
are affected in the same manner in cancer patients. This was already observed by 
Winter et al. in canine lymphoma patients were a decrease of Vitamine E was 
followed by an independent increase of other BAP’s components, resulting in a 
partial compensation of the BAP. However, it is important to note that BAP seems 
to be still high in cancer patients both in our study than in the ones reported below 
(Vajdovich, 2005; Winter, 2009) and antioxidant administration might not prove to be 
clinically beneficial as supplementation of vitamin E or other antioxidants could 
diminish the efficacy of certain chemotherapeutic agents by reducing the 
production of ROS. Further studies will be needed to evaluate the relative benefits 
and risks of antioxidant supplementation. 
In vitro studies purposed the role of Vitamin E in prevents mediator release by 
mast cells (Gueck, 2002; Kempna, 2004) but in our population we observed no 
significant correlation of Vitamin E serum concentration values and MCT clinical 
sub stage. Otherwise further studies should be performed including more MCT in 
high clinical stage (stage 4). 
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In veterinary medicine there are no studies which used the methods used in this 
thesis for the evaluation of BAPs and ROMs in cancer patients, thus the ones 
described early focused on single molecules. In humans, evaluating BAPs and 
ROMs in a way similar to the one we used in this thesis, it was concluded that 
oxidative status might be a useful clinical marker for the evaluation of malignant 
grades and clinical stages of non hodgkin lymphoma (Nojima, 2011). Moreover in 
another study the level of ROMs were higher in lung cancer patients than in 
normal subjects, thus ROMs seems to be altered in most of the neoplastic disease 
(Katsabeki-Katsafli, 2007). The same authors found a significance difference in serum 
VEGF levels between lung cancer patients and healthy control subjects. Also in 
our study healthy control patients had a significant lower VEGF serum 
concentration compared with epithelial and MCT patients. Is interesting how our 
healthy control group had a detectable VEGF serum level in disagreement with the 
results of Troy et al (2006) were healthy patients had an undetectable serum  
VEGF in more than 90% of the cases. This could be related with the different 
antibodies used for the ELISA assay: canine in this study and human in Troy et al. 
The present study failed in finding a significant correlation between VEGF and 
ROMs, although VEGF has been found to be up-regulated by conditions 
associated with the generation of free radicals and reactive oxygen intermediates 
(oxidants) (Maulik, 2002). In the study of Wergin et al (2004) serum VEGF in 
canine patients was found to be related with the malignancy of the neoplastic 
disease in epithelial and mesenchimal tumours, on the contrary in the study of 
Patruno et al. (2009) this was not observed in canine MCT were the serum VEGF 
was not related with histophatological grading and or clinical staging while a 
relation was present for cytosol VEGF. Our results on serum VEGF in MCT 
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appeared to be in agreement with Patruno et al. (2009). Concerning iron status it 
was observed that ferritin was higher in cancer patients as it was in non neoplastic 
disease compared to the healthy patients. This maybe suggests that ferritin is not 
a specific marker for cancer and may behave as a positive acute phase protein 
also in these patients. However ferritin was also positively correlated with VEGF in 
our cancer patients and this could be related with a role of VEGF not only as a 
neoangiogenetic factor but maybe also as an acute phase protein. In conclusion, 
these data add interesting information on iron serum status, serum VEGF and 
oxidative stress pattern in oncologic patients. Oxidative stress and VEGF 
appeared both significantly increased in patients with mast cell and epithelial 
tumors. 
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